Western Michigan University

ScholarWorks at WMU
Master's Theses

Graduate College

4-2007

Biochemical Characterization of Disease-Causing Mutation in NTerminal Wilson Protein Domain Six
Patrick Ochieng

Follow this and additional works at: https://scholarworks.wmich.edu/masters_theses
Part of the Chemistry Commons

Recommended Citation
Ochieng, Patrick, "Biochemical Characterization of Disease-Causing Mutation in N-Terminal Wilson
Protein Domain Six" (2007). Master's Theses. 4551.
https://scholarworks.wmich.edu/masters_theses/4551

This Masters Thesis-Open Access is brought to you for
free and open access by the Graduate College at
ScholarWorks at WMU. It has been accepted for inclusion
in Master's Theses by an authorized administrator of
ScholarWorks at WMU. For more information, please
contact wmu-scholarworks@wmich.edu.

BIOCHEMICAL CHARACTERIZATION OF DISEASE-CAUSING MUTATION IN
N-TERMINAL WILSON PROTEIN DOMAIN SIX

by
Patrick Ochieng

A Thesis
Submitted to the
Faculty of The Graduate College
in partial fulfillment of the
requirements for the
Degree of Master of Science
Department of Chemistry

Western Michigan University
Kalamazoo, Michigan
April 2007

Copyright by
Patrick Ochieng
2007

ACKNOWLEDGEMENTS
First, I want to thank the Chemistry Department of Western Michigan University
for giving me the opportunity to pursue my graduate studies in chemistry. I also want to
thank my research advisor Dr. David Huffman, for his continuous support during my
masters program. Dr. Huffman particularly introduced me to competitive research in
Western Michigan University by involving me in the Wilson disease project. Through his
NIH grant, he was able to support me and my research for six months while at the Centre
for Magnetic Resonance (CERM), Italy and also at Western Michigan University. Thanks
also for the valuable corrections and suggestions he made on this thesis. I would also
want to thank our collaborators at the University of Florence Italy, for the fellowship they
awarded me to conduct part of this research in their magnificent NMR facility. Thanks to
Prof. lvano Bertini, Prof. Lucia Banci and Dr. Simone Ciofi-Baffoni for the mentorship
they gave me while in CERM.
Besides my advisors, I would like to thank my thesis committee members; Dr.
Sherine Ohare and Dr. Dongil Lee for their support and availability in my committee
meetings. Thanks also for their insightful comments and review of my thesis on a short
notice. Last, but not least, I thank my wife Lilly for the support she gave me during my
masters program. She has also been an inspiration throughout this journey.
Patrick Ochieng

11

BIOCHEMICAL CHARACTERIZATION OF DISEASE-CAUSING MUTATION IN
N-TERMINAL WILSON PROTEIN DOMAIN SIX
Patrick Ochieng, M.S.
Western Michigan University, 2007
Wilson protein (ATP7B) is a copper-transporting P-type ATPase that regulates
copper homeostasis and secretion of copper-containing enzymes in the liver. In
hepatocytes, ATP7B delivers copper to apoceruloplasmin and mediates the excretion of
excess copper into bile. Mutation in the gene coding for Wilson protein leads to Wilson
disease. Several mutations in Wilson protein have been identified and of particular
interest, mutations affecting the N-metal binding region significantly interfere with the
ability of Wilson protein to transport copper to its target in the copper-trafficking
pathway. In an attempt to characterize the disease-causing mutation (G591D) in Wilson
protein domain 6 (WLN6), we have sub-cloned, overexpressed, purified and structurally
characterized the native domain 6 construct of Wilson protein using NMR. We have also
expressed the G591 D mutant form of the same domain in GST fusion for comparison
studies. Solution NMR results indicate that native WNL6 is monomeric and well-folded
with a

pappap

ferroxidin-like structure. Subsequent structural determination of this

mutant with NMR will reveal more about the effect of this mutation.
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CHAPTER I
INTRODUCTION
Importance of copper and homeostasis
The association between the nutrient copper and normal hemoglobin metabolism,
a vital physiological process, was recognized in the middle of the 19th century (Fox,
2003). Over the next 150 years, approximately a dozen proteins dependent on copper for
their function ( cuproenzymes) were discovered (Failla et al., 2001). These cuproenzymes
explain why dietary copper is essential, because copper restriction in the diet can alter the
activity of a cuproenzyme and impact normal physiology. Copper plays a key role in aU
living organisms serving as a cofactor for many enzymes and proteins involved in
electron transfer (cytochrome c oxidase), melanin production (tyrosinase), production of
neurotransmitters (dopamine-�-hyroxylase), collagen cross-linking (lysyl oxidase) and
detoxification of oxygen radicals (superoxide dismutase) (Yuan et al., 1995). An example
of the importance of copper is hereby outlined: In melanocytes the copper redox center
of tyrosinase converts tyrosine to dihydroxyphenylalanine in the first step in the synthesis
of the pigment melanin. Hypopigmentation is a consequence of dietary copper deficiency
due to limiting tyrosinase. Other details of the nutritional biochemistry of copper have
been summarized elsewhere (Prohaska, 1988). Excess copper inside the cells is also
toxic. Some of the toxic effects of increased copper levels inside the cell include DNA
damage, inactivation of certain enzymes and lipid peroxidation (Gu et al., 2000). Excess
copper(!) in the cells can also disproportionate to elemental copper whose interaction
with hydrogen peroxide gives superoxide species which may lead to oxidative damage of
cells (DiGuiseppi & Fridovich, 1984).
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It is recommended that adults consume at least 0.9 mg of copper daily and restrict
their intake to <10 mg daily to prevent overt signs of copper deficiency and toxicity,
respectively (Trumbo et al., 2001). Cells have therefore developed a tight-lipped
homeostatic mechanism through which the uptake, distribution, secretion and the efflux
of copper is mediated. The accomplishment of copper homeostasis and other toxic metals
is still not yet fully understood and this represents a central problem in bioinorganic
chemistry. The importance of understanding how metal ions are handled within cells is
underscored by recent research linking a number of human diseases to deficiencies in
metal ion trafficking pathways.
· The molecular details of intracellular copper trafficking have been the centre of
focus towards understanding the mechanisms of copper transfer and excretion. The
discovery of copper handling proteins; copper chaperones (metallochaperones) and
copper transporting ATPases has shed some light in copper regulation and transport.
Proteins involved in the uptake, distribution, secretion and efflux of copper include high
affinity permeases for copper uptake, copper chaperones for distribution to target copper
requiring proteins and copper transporting P-type ATPases which transport copper in the
secretory pathway and export copper when in excess (Huffman & O'Halloran, 2001;
Prohaska & Gybina, 2004). The liver plays a very crucial role in copper balance in the
body. Most copper absorbed from the intestine is received by the liver. Also biliary
excretion is closely connected to the liver (Tao & Gitlin, 2003).
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Intracellular copper pathways
Elevated copper levels inside the cell are harmful for the cell. Copper proteins in
the body however, require threshold amounts of copper for either enhancement of their
activities or for transport to its target in the copper transport pathway. Therefore a
sequential mechanism through which this process is accomplished must be realized for
the homeostatic balance to be attained. Copper acquisition, utilization and export is
orchestrated by a series of copper permeases, copper chaperones and copper transporting
ATPases (Huffman & O'Halloran, 2001).
In humans the Ctr1 permeases transports copper from the extracellular matrix into
the cell (Kuo et al., 2001). Before uptake inside the cell copper is first reduced from Cu+
to Cu2+ by a mechanism which is still not well understood (Lee et al., 2002; Puig et al.,
2002). Once inside the cell, copper is acquired by the chaperones, CCS for superoxide
dismutase (Casareno et al., 1998) and Hahl (also called Atoxl ) (Klomp et al., 1997) for
Wilson protein and/or Menk.es protein. Figure 1 shows a schematic representation of how
this transfer is accomplished. In humans, Atoxl delivers copper to the membrane
associated copper-transporting ATPases. Wilson disease protein (WLNP) and Menk.es
disease protein (MNKP) ultimately use the energy derived from ATP hydrolysis to
translocate copper into the secretory pathway and to export excess copper into the bile
(Hung et al., 1997). CCS delivers copper to Cu/Zn superoxide dismutase (SOD) while the
chaperone that delivers copper to cytochrome c oxidase is still unknown. Recent studies
indicate the possibility of mitochondrion matrix copper complex being the copper source
for cytochrome c oxidase (Cobine et al., 2006). Other putative copper handling proteins
include Murrl (a recently discovered protein whose absence results in canine copper
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toxicosis) (Klomp et al., 2003; Tao et al., 2003), metallothionine (MT-1 and MT-2) and
amyloid precursor protein (APP) (Kong et al., 2007).
There has been remarkable conservation of the copper-binding sites in the
metallochaperones and ATPases from bacteria to mammals (Arnesano et al., 2002). For
example, the sequence M-X1 -C-X11-X111-C is highly conserved. X1 is usually S, T, or H,
and X 111 is G in metallochaperones and S or A in A TPases. This suggests that these
proteins are functionally related or belong to the same pathway. Analogous to the
mechanism of copper trafficking in humans is the proposal that there is a similarity
through which the yeast metallochaperone Atx1 delivers copper to its target Wilson
protein homologue, Ccc2 (Pufahl et al., 1997).

?

/
.�0

► Cyt. C
Oxidase

______. ◄

Ceruloplasmin

@__.@

ATOX1

\ccs

r2J

►..

/Zn SOD

Figure 1. The copper trafficking pathways in hepatocyte. Cox 17, Atoxl and CCS are
copper chaperones. Cytochrome c oxidase, Wilson/Menkes protein and Cu/Zn SOD are
copper target proteins. TGN is trans-Golgi network.
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Wilson Disease (WD)
Wilson disease, or hepatolenticular degeneration (Wilson, 1912), is a
neurodegenerative disease of copper metabolism. Patients accumulate copper in the liver,
kidneys and brain (Cumings, 1948). Later, more symptoms observed included renal
dysfunction (Brewer & Yuzbasiyan-Gurkan, 1992), reduced copper incorporation in
ceruloplasmin (Scheinberg & Gitlin, 1952) and impaired billiary excretion (Frommer,
1974; Stemlieb, 1984). Mutations in the ATPB7 proteins lead to disruption of normal
copper distribution leading to Wilson Disease (Cox, 1996; Moore & Cox, 2002). Wilson
disease involves loss of the ability to export copper from the liver into bile and to
incorporate copper into hepatic ceruloplasmin. Accumulation of copper in the cytoplasm
of hepatocytes results in cellular necrosis and leakage of copper into the plasma. The
excess copper then collects in extrahepatic tissues, including the basal ganglia and the
limbus of the cornea (Walter et al., 2005).
Wilson disease incidence is 1 m 35,000-100,000 live births, with a gene
frequency of 0.56% (Gollan & Gollan, 1998). The treatments that have been used to
contain Wilson disease include agents such as BAL (2,3-dimercaptopropanol), D
penicillamine, zinc acetate, TRIEN (triethylenetetramine), and tetrathiolmolybdate. BAL,
D-penicillamine, TRIEN, and tetrathiomolybdate are copper chelating agents which
remove excess copper from the body. Zinc salts and tetrathiolmolybdate prevent the
uptake of copper by the intestinal cells and increase fecal excretion (Brewer et al., 2003).
Although the animal models are not human equivalents of Wilson disease, they
are helpful in studying copper metabolism and potential treatments. The Bedlington
terrier has an autosomal recessive inherited disease characterized by copper toxicosis
(Klomp et al., 2003). The Bedlington terrier does not develop neurological symptoms,
5

but its liver pathology is similar to that of Wilson disease. Canine copper toxicosis is
caused by a mutation of the MURRI gene, which is also believed to be essential for ·
copper excretion and downstream of the gene that causes Wilson disease.

Menkes Disease (MKD)
The importance of copper homeostasis is underscored by Menkes and Wilson
diseases (Culotta & Gitlin, 2001). In 1962, John Menkes, MD, and his colleagues at
Columbia University in New York published a scientific article about 5 male infants with
a distinctive genetic syndrome (Menkes et al., 1962). This syndrome, now known as
Menkes kinky hair disease, has been identified as a disorder of copper metabolism in the
body. Some parts of the body don't have enough copper (blood plasma, liver, and brain),
while other parts of the body (kidney, spleen, skeletal muscle) accumulate too much.
Menkes disease is characterized by copper deficiency due to defective transport across
the placenta and intestinal uptake of copper (Schaefer & Gitlin, 1999). Copper transport
across blood the brain barrier is also impaired leading to severe copper deficiency in the
central nervous system (Danks, 1995). Menkes disease is caused by mutations in the gene
coding for the Menkes disease protein, MNKP. The major symptoms include
neurological defects, weak muscles and poor growth which usually eventually leads to
death (Schaefer & Gitlin, 1999). Menkes disease is estimated to occur anywhere from 1'
individual per 100,000 live births to 1 in 250,000 live births (Danks, 1980). Logically, it
would seem that if copper could get to the cells and organs that need it, the disorder
would be lessened. Researchers have tried giving intramuscular injections of copper, with
mixed results. It does seem that the earlier in the course of the disease that the injections
are given, the more positive the results. Milder forms of the disease respond well, but the
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severe form does not show much change. Intravenous administration of copper-histidine
complex is being used as a preferred treatment (Christodoulou et al., 1998).

Wilson Protein (WLNP)
Wilson disease protein (WLNP) is a copper-transporting P-type ATPase (Bull et

al., 1993; Tanzi et al., 1993) that plays a key role in copper distribution in the liver,
kidney and the brain (Lutsenko & Petris, 2003). Immunocytochemical studies have
demonstrated that Wilson protein is localized in the trans-Golgi network (Hung et al.,
1997; Yang et al., 1997) and exhibits a copper-dependent translocation to a cytoplasmic
vesicular compartment (Guo et al., 2005). Other studies have confirmed that the amino
terminus of this protein binds copper (DiDonato et al., 1997; Lutsenko et al.; 1997) and
expression of the human Wilson protein in ccc2t,,, yeast lacking the homologous ATPase
(Iida et al., 1998) and in the LEC rat, an animal model of WLNP (Wu et al., 1994;
Yamaguchi et al., 1994), demonstrates restoration of cuproprotein synthesis, indicating a
direct role for the Wilson protein in copper transport (Hung et al., 1997; Terada et al.,
1998).
WLNP utilizes the energy of ATP hydrolysis to transport the metal into the
secretory pathway for incorporation into copper-dependent enzymes such as
ceruloplasmin (a multi-copper oxidase) and to export excess copper from the cell
(Lutsenko & Petris, 2003). Upon elevated copper levels, Wilson protein translocates from
its normal position in the trans-Golgi network to the post-Golgi cytoplasmic vesicular
compartment, where it is responsible for biliary excretion of copper. (Hung et al., 1997).
Mutations in Wilson protein leads to the disruption of normal copper distribution, leading
to a severe pathological disease in humans known as Wilson disease. Wilson disease
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(WD) is an inherited disorder of copper metabolism characterized by hepatic cirrhosis
and neuronal degeneration caused by a marked impairment in biliary copper excretion
(Cox, 1996; Cuthbert, 1998). Another copper-transporting ATPase carrying out a similar
function to Wilson protein is Menkes protein. Mutations in Menkes protein also lead to
Menkes disease, a copper deficiency disorder. WLNP and other eukaryotic copper
ATPases are unique among the P-type ATPases because they do not bind copper directly
from the cytosol (where the amounts of free copper are low, (Rae et al., 1999)), instead
the copper is delivered to these ATPases by metallochaperones facilitated by protein
protein binding and subsequent exchange of copper to the metalloprotein (Banci &
Bertini & Cantini & Felli et al., 2006). Atoxl (Hah 1) serves as the metallochaperone for
WLNP (Figure 1).
Wilson Protein has six N-terminal metal binding regions (domains, MBDs), each
of which contains a conserved amino acid sequence GMXCXXC (where X can be any
amino acid). The cysteine residues in the consensus sequence of each motif are
responsible for copper binding during the copper transfer mechanism (Huffman &
O'Halloran, 2001). Structure-based sequence alignments have also predicted the tertiary
structure of these individual domains to exhibit a pappap conformation (Arnesano et al.,
2002). Achila et al. have resolved the NMR solution structure of two of the six N
terminal metal binding domains 5 and 6 (WLN5-6) of Wilson protein (Achila et al.,
2006). The solution NMR structure of WLN5-6 supports the

pappap

structure

prediction of a bis ferrodoxin fold. NMR structures of several N-terminal domains of
Menkes protein have been shown to exhibit the same conformation (Banci et al., 2004;
Banci & Bertini & Cantini & Chasapis et al., 2005; Banci & Bertini & Cantini &
Migliardi et al., 2005; Banci & Bertini & Ciofi-Baffoni et al., 2005; Banci & Bertini &
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Cantini & DellaMalva et al., 2006) suggesting that these proteins carry out similar
functions. WLNP is composed of an N-terminal metal binding domains, eight
transmembrane domains, an ATP binding domain (composed of 2 domains, the P domain
and the N-domain) and the actuator domain based on similarity to the sarcoplasmic
reticulum Ca2+ ATPase (Toyoshima et al., 2000;

Toyoshima & Nomura, 2002;

Toyoshima & Mizutani, 2004).

Metal Binding Domains (MBDs) in WLNP and MNKP
Both Wilson and Menkes proteins have six metal binding domains in the Nterminus. The individual domains are about 72 amino acids long and share about 20-60%
homology. This low similarity suggests that these domains may be functionally non
equivalent, especially with respect to interaction with the copper chaperone, Atox 1
(Achila et al., 2006; Banci & Bertini & Cantini & Chasapis et al., 2005). The solution
NMR structure of Menkes protein domain 4 exhibits a compact ferrodoxin-like �a��a�
fold (Gitschier et al., 1998) and the same fold is predicted for each of the individual metal
binding domains of WLNP.
A copper binding site CXXC is housed in the highly conserved motif GMTCXXC
which forms a loop within each of the metal binding sites. Conserved residues in all the
metal binding sites are found in this loop thereby forming a suitable environment
necessary for accepting copper from intracellular copper donors such as Atox 1
(Wernimont et al., 2004). Copper induced conformational analysis shows that both the
secondary and the tertiary structural changes take place upon copper binding. These
changes are thought to play both regulatory and functional roles (DiDonato et al., 2000).
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Function of the N-terminal Metal Binding Domains (MBD)
A number of studies have been carried out attempting to elucidate the function of
the N-terminal metal binding domains. In heterologous assays in ccc2� yeast, mutations
in the N-metal binding domains ofWLNP and MNKP closest to the membrane portion of
the enzyme hinder their ability to transport and incorporate copper into the yeast
ceruloplasmin homologue, Fet3 (Forbes et al., 1999; Iida et al., 1998). The second and
third metal binding sites could not substitute for the sixth MBD in loading copper into
Fet3. Moreover, a study done using WLNP variants with mutations or truncations in the
N-terminal domains found that copper stimulates catalytic activity cooperatively and that
this requires the presence of MBDs 5 and 6 (Huster & Lutsenko, 2003). Metal binding
domains 5 and 6 also seem to be the most critical for copper trafficking from the trans
Golgi to plasma membrane in higher eukaryotes (Cater et al., 2004).

All lower

eukaryotes and some prokaryotes possess at least two MBDs close to the membrane
portion of the copper pump (Arnesano et al., 2002). The spatial separation of each of the
WLNP metal binding domains within the N-terminus may help facilitate interactions
between domains of WLNP. Each of these ~ 72 residue domains are connected to one
another by a linker: 11 residues betweenWLNl and WLN2, 42 residues between WLN2
and WLN3, 30 residues between WLN3 and WLN4, 57 residues between WLN4 and
WLN5 and 8 residues betweenWLN5 andWLN6.

Transmembrane domains
The derived amino acid sequence of the Wilson's disease gene reveals the
presence of motifs conserved in all members of the P-type family of cation transport
proteins. The prototypes of this family include the Ca2+-ATPase in the sarcoplasmic
10

+

+

+

+

reticulum, the Na /K -ATPase on the plasma membrane, and the H /K -ATPase in the
cells lining the stomach. Each of these ATPases contains a consensus ATP-binding
domain (GDGVND) and an aspartate residue (DKTGT) used to form the aspartyl
phosphoryl intermediate essential for ion transport (Lutsenko & Petris, 2003; Pedersen &
Carafoli, 1987).
+
Ca2 -ATPase is composed of three major domains. The TM (transmembrane)

domain consists of 10 TM segments and forms sites for binding and translocation of ions.
It is linked to a cytosolic ATP-binding domain, which contains the catalytic site, and to
+

an actuator domain, which plays an important role in conformational transitions of Ca2 ATPase. In turn, the ATP-binding domain was shown to consist of two structural units
connected by a linker: the P-domain, which houses the DKTG motif (a site of catalytic
phosphorylation) and the N-domain, which contributes to the binding of nucleotides
+

(Toyoshima et al., 2000). In contrast with Ca2 -ATPase, very little is known about the
structure and the mechanistic properties of WLNP. Although the membrane structure of
the Wilson ATPase has not been experimentally determined, hydropathy plot analysis
and site-directed mutagenesis suggests a protein with eight transmembrane domains
where the amino and carboxyl terminus are located on the same side of the membrane
(Bull & Cox, 1994). In addition to the consensus sequences noted above, the Wilson
ATPase contains one additional region, a CPC sequence in the sixth transmembrane
domain, which is conserved in all heavy metal membrane transporters (Lutsenko &
Kaplan, 1995; Solioz & Vulpe, 1996). In the case of the Wilson ATPase, these three
amino acids are essential for copper transport, implying a role for these cysteines in metal
binding (Payne et al., 1998; Schaefer & Gitlin, 1999). Other studies (Tsivkovskii et al.,
2002) demonstrated that WLNP undergoes catalytic phosphorylation at D1027 in the
11

DKTG motif, as expected for the P-type ATPases. Studies also found that the mutation
H1069Q (the most frequent mutation in patients suffering from Wilson's disease) disrupts
catalytic phosphorylation from ATP, suggesting that Hl069 plays an important role in
ATP binding (Tsivkovskii et al., 2003). In fact, the most recent analysis of this frequent
disease mutation, Hl069Q, demonstrates that it does not significantly affect the structures
of the N-domain, but prevents tight binding of ATP (Dmitriev et al., 2006). Several other
disease-causing mutations have been identified in the ATP-binding domain of WLNP.
Whereas for some of them the effect on WLNP function can be predicted (e.g., the
mutation Tl031I adjacent to the DKTG motif will probably disrupt catalytic
phosphorylation), the specific consequences of other mutations are still unclear.

Phosphorylation of WLNP and MNKP
WLNP belongs to a large family of P-type ATPases. During their catalytic cycle,
the P-type ATPases become transiently phosphorylated at the invariant aspartic acid
residue in the sequence motif DKTG located in the ATP-BD (ATP-binding domain) of
the protein (Lutsenko & Petris, 2003). The structural and functional properties of several
members of this family, such as Ca2+-ATPase of SR (sarcoplasmic reticulum) and plasma
+

+

membrane Na , K -ATPase have been studied fairly extensively. For example, the high
+

resolution structure of SR Ca2 -ATPase has been determined in two conformational states
(the calcium-bound form, El (Toyoshima et al., 2000), and the calcium-empty form in a
complex with thapsigargin, E2 (Toyoshima & Nomura, 2002), providing the structural
basis for understanding the mechanism of the ATP-driven ion transport. Similarly, a
solution NMR structure of the N-domain of ATP7b has been resolved recently (Dmitriev
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et al., 2006). The N-domain consists of a six-stranded P-sheet with two adjacent a-helical
+

hairpins and, unexpectedly, shows higher similarity to the bacterial K -transporting
+

+

+

ATPase KdpB than to the mammalian Ca2 -ATPase or Na , K -ATPase. The common
core structure of P-type ATPases is retained in the 3D fold of the N-domain; however, the
nucleotide coordination environment of ATP7B within this fold is different. The residues
H1069, G1099, Gl 101, I l 102, Gl 149, and N l 150 conserved in the P(lB)-ATPase
subfamily have also been shown to contribute to ATP binding (Dmitriev et al., 2006).
Besides its role as. a cofactor, copper has been shown to regulate crucial post
transcriptional

events

such

as

protein

phosphorylation.

Copper

modulates

phosphorylation of its key transporter in humans WLNP (Vanderwerf et al., 2001).
Copper induced phosphorylation was observed to be fast and specific and correlates with
the intracellular location of WLNP. Copper induced phosphorylation also requires the N
terminal domains (Vanderwerf et al., 2001). It was proposed by the authors that WLNP
phosphorylation could be among the molecular mechanisms by which copper regulates
its own metabolism.
MNKP is transiently phosphorylated by ATP in a copper specific and dependent
manner and appears to undergo conformational changes in accordance with classical Ptype ATPase model (Voskoboinik et al., 2001). The data obtained from this study also
suggest that the catalytic cycle of MNKP protein begins with the binding of copper to the
high affinity binding sites in the transmembrane channel followed by ATP binding and
transient phosphorylation.

+

Recent studies show that Cu interacts with MNKP m a

cooperative manner to regulate phosphorylation (Hung et al., 2007).
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Regulation of WLNP and MNKP
Even though copper uptake through Ctr 1 is a critical step in the supply of copper
to the liver cells, the continuous accumulation of copper in hepatocytes of WD patients
suggests that copper homeostasis is not regulated at the uptake level (Gitlin, 2003).
Atox I-mediated copper transfer activates WLNP (Walker et al., 2002). Studies have
shown that Atoxl can transfer copper to N-terminal WLNP as well as remove copper
from the same region after incubation with apo-Atoxl (Walker et al., 2002) and
apparently down-regulation of WNDP activity. This suggests that both apo and
metallated forms of Atoxl may contribute to the regulation of WLNP activity (Walker et

al., 2002).
Copper binding to N-terminal WLNP induces a metal-specific conformational
change in WLNP protein (DiDonato et al., 2000). Analysis of copper-induced
conformational changes in the amino-terminal domain indicates that both secondary and
tertiary structure changes take place upon copper binding (DiDonato et al., 2000). These
copper-induced conformational changes could play an important role in the function and
regulation of the ATPase in vivo (Fatemi & Sarkar, 2002). This theory is also supported
by experiments showing that copper occupancy of WLNP affects its intracellular
localization, post-transcriptional modification and activity (Vanderwerf et al., 2001).
Other studies using rCBD, an N-terminal rat homologue of WLNP, also show a
metal induced secondary and tertiary structural changes similar to the one observed for
WLNP (Tsay et al., 2004). Analysis of the UV and CD spectra of rCBD suggests that
+

Cu

binding to N-terminal domains induces the conformational change. These

observations support the theory of regulation by the copper substrate (DiDonato et al.,
2002).
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Metal binding, coordination and metal ion specificity
Circular Dichroism (CD) and X-ray absorption Spectroscopy (XAS) have been
+

used to characterize Zn binding to N terminal WLNP. Zn2 is able to bind to this domain
with a 6.5:1 stoichiometry (DiDonato et al., 2002). Extended X-ray Absorption Fine
Structure (EXAFS) experiments show that MBD2 (Walker et al., 2004) and Atoxl (Ralle

et al., 2003; Ralle et al., 2004) both bind Cu+ with a linear co-ordination and the distance
+

between sulfurs in the cysteine residues to Cu is 2.16

A

in each protein. Electron

Paramagnetic Resonance (EPR) analysis of copper bound MBDl of MNKP showed no
signal (Jensen & Bonander & Hom et al., 1999). This confirms that copper-bound to
+

MBD1 is in the +1 oxidation state and not +2. Cu was also observed to bind to apo
MBD1 of MNKP in a 1:1 stoichiometry with an apparent Kct of 46 µM. However,
+

oxidized MBDl does not bind Cu (Jensen & Bonander & Hom et al., 1999). Both N
+

WLNP and N-MNKP bind Cu with a stoichiometry of roughly 1:6 (DiDonato et al.,
1997; Jensen & Bonander & Moller et al., 1999) suggesting that each of the six metal
binding domains is involved in copper coordination. The apparent affinity constants for
copper binding to WLNP N-terminal copper binding domains determined by isothermal
titration calorimetry reveal similar values (Ka ~105 -106) for all the domains (Wernimont

et al., 2004) which is on the same order as that measured for N-MNKP MBDs (Jensen &
Bonander & Moller et al., 1999).
Despite the high sequence similarity in Pl-type ATPases, each ATPase is very
discriminative in transporting its corresponding metal ions. For example ZntA, an E. coli
+

+

P-type ATPase is specific for Pb2\ Zn2 , Cd2+ and Hg2 while WLNP, MNKP and Cop A
+

+

transport Cu and possibly Ag (Mitra & Sharma, 2001). A related study showed that
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+

+

Zn2 binds WLNP but is ligated to nitrogen atoms, not sulfur as for Cu (DiDonato et al.,
2002). This binding also induces conformational change on the protein. However, the
conformational change is different and this may suggest a structure-based mechanism for
discrimination of metal ions in vivo.
WLNP and MNKP have been found to be discriminative in the metal ion they
bind and transport copper ions across the membrane. A study using immobilized metal
ion chromatography reveals that the fusion protein of N-WLNP is able to bind transition
+

+

+

+

metals with varied affinities as follows Cu >>Zn2 > Ni2 >Co2 . N-WLNP shows no
+

+

+

+
affinity for ca2 , Mg2 , Fe2 , and Fe3 (DiDonato et al., 1997).

Atx1-like copper chaperones
Metallochaperones are intracellular proteins that bind and deliver metal to specific
partner proteins (Pufahl et al., 1997). The oxygen toxicity of yeast mutants lacking Cu,
Zn-superoxide dismutase (SOD) can be suppressed by the expression of a small
antioxidant protein, Atx1, which was subsequently shown to be a copper chaperone (Lin
& Culotta, 1995; Lin et al., 1997). Shortly after the yeast work was published, a homolog
in humans and other mammals, Atox1, was discovered (Klomp et al., 1997). Human
+

Atoxl contains 68 amino acids. Once Cu enters a cell, it binds to the copper-binding site
of Atox1 and is transferred to its docking partners in the secretory pathway (Fig.1). Atox1
interacts with ATP7B in the hepatocyte and is thus required for proper biliary excretion
of excess copper as well as delivery of copper for holoceruloplasmin (CP) synthesis. In
yeast, two metallochaperone mediated copper delivery pathways have been characterized
+

in detail (Figure 1). Atx1 is a 73 amino acid protein that binds Cu (Pufahl et al., 1997)
and delivers it to the P-type ATPase Ccc2 (Huffman & O'Halloran, 2000) for
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translocation across intracellular membrane and loading into multicopper oxidase Fet3
(Yuan et al., 1995). Fet3 is then localized to the cell surface where it is proposed to
+

+

oxidize Fe2 to Fe3 for transport across the plasma membrane (de Silva et al., 1997).
Deletion of the gene encoding Atxl in yeast cells results in defects in high affinity iron
uptake (Lin et al., 1997). Expression of the human Atx1 homologue Hah1 restores iron
uptake in hahl� yeast, consistent with the presence of an analogous pathway in humans
(Klomp et al., 1997). In another experiment deletion of the Atox 1 gene in mice causes
perinatal mortality (Hamza et al., 2001). Atox1-null mice exhibit hypopigmentation
consistent with a role for Atox1 in copper delivery to tyrosinase (Prohaska, 1988). The
skin distortion is likely due to reduced levels of lysyl oxidase, a cuproenzyme involved in
elastic and collagen cross-linking. Copper levels in the liver and brain are decreased by
50% in mutants, consistent with an impaired efflux of copper from enterocytes (Hamza et
al., 2001). Cells lacking Atox1 have impaired movement of ATP7A in response to
copper, providing a mechanistic explanation for copper retention (Gitlin, 2003). ATP7A
normally resides in the trans-Golgi membrane but moves to the plasma membrane when
cellular copper concentrations rise (Monty et al., 2005). In addition to its chaperone
function, other properties may be ascribed to Atoxl. Atoxl is present at high levels in
neurons and may protect these cells from oxidative stress (Klomp et al., 1997).
The copper-trafficking pathway in yeast has been extensively studied and much
+

+

+

has been proposed. The reactivity of aqueous Cu and relative stability of Cu in Cu +

Atxl suggests that the coordination environment of Atxl stabilizes the Cu state,
+

suppressing the disproportionation of Cu to Cu2+ (aqueous) and Cu (Pufahl et al., 1997).
A direct, copper-dependent interaction between Atxl and the first N-terminal domain of
Ccc2 (Ccc2a) has been shown (Huffman & O'Halloran, 2000; Pufahl et al., 1997).
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+

Using this knowledge and the coordination chemistry of Cu -Atxl, a mechanism for
copper exchange between Atx 1 and Ccc2a has been proposed. The authors suggest that
+

Cu is transferred from one protein to another through two- and three-coordinate
intermediates.
An in vitro metal transfer assay has been developed to study the copper
+

trafficking pathway in yeast. Cu -Atxl was mixed with apo-Ccc2a and separated using
anion exchange chromatography. Using this assay, it was found that copper rapidly
equilibrates between Atx 1 and Ccc2a with an equilibrium constant of exchange (Kexchange)
slightly > 1 (Huffman & O'Halloran, 2000). The transfer occurs in the presence of copper
chelators, supporting the hypothesis that the copper exchange occurs through direct
protein-protein interaction. Experiments repeated with Hg-Atxl established that Hg-Atxl
+

is able to function as a model for the Cu form of Atxl (Cu-Atxl) (Rosenzweig et al.,
1999).
Hahl, a human homologue of Atxl, has been shown to interact with Wilson
Protein, a human homologue of Ccc2. Hahl is localized to the cytoplasm and nucleus,
and its interaction with WLNP is specific and copper-dependent (Hamza et al., 1999).
This interaction is impaired in WLNP with mutations that result in Wilson disease. In a
GST column-binding assay, a smaller amount of the Wilson protein disease-causing
mutants was retained on a GST-Hahl column than the wild-type WLNP suggesting that
there is poor interaction between mutant WLNP and its metallochaperone, Hahl (Hamza
et al., 1999). A yeast two-hybrid system has been used to study the interaction and
transfer of copper from Atoxl to various N-terminal domains of WLPN (Larin et al.,
1999).

The metal-specific interaction between Atoxl and WLNP requires cysteine

residues. The copper-transporting ability of Atoxl has also been shown to protect
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neuronal cells from high copper concentration (Kelner et al., 2000). This suggests that
Atoxl could be involved in copper regulation in the body.
The homology between the human and yeast copper-trafficking systems have
resulted in extending studies of the yeast system to the human system. There is new
evidence for direct protein-protein interaction (Banci & Bertini & Cantini & Felli et al.,
2006), showing how the proteins interact and the molecular factors that define the
proteins specificity. The determination of a high-resolution 1.02 A X-ray structure of
Hg-Atxl has contributed to the understanding of the surface characteristics important for
interaction (Rosenzweig et al., 1999). The pappap secondary structural domain of Atxl
places it in a structural class with the domain four of the MNKP (Gitschier et al., 1998).
The structural homology between Menk.es 4 and Atx1, suggesting that Ccc2a and Ccc2b
may also have a structure similar to Atx1, was shown in the NMR structure of Ccc2a
(Banci et al., 2001).
The crystal structure of Hg-Atxl (Rosenzweig et al., 1999) and its relationship to
other copper-transporting proteins provides information about the residues important for
protein interaction and metal transfer. There are 10 lysine residues on the surface of
Atxl. Menk.es protein domain 4 has multiple negatively charged residues (aspartate and
glutamate) on the surface. It was hypothesized that some of these residues of Atxl could
interact with acidic residues on the surface of Ccc2 (Rosenzweig et al., 1999). In support
of this hypothesis, it has been demonstrated that the lysine residues on the surface. of
Atxl are critical for the delivery of copper from Atxl to Ccc2 (Portnoy et al., 1999).
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Copper Chaperone, CCS
The second copper chaperone to be recognized, CCS, is a protein required for the
delivery of copper to SOD under copper limiting conditions. This chaperone was
discovered by Valerie Culotta and colleagues (Culotta et al., 1997). CCS is a homodimer
with 35-k:Da subunits and 3 functional domains. Domain 2 is highly homologous to SOD.
Heterodimer pairs of SOD and CCS subunits form to facilitate copper transfer (Rae et al.,
1999; Schmidt et al., 1999). Domain 1 contains the MXCXXC copper-binding site but
essential cysteines in domain 3 are involved in the transfer of copper to apoprotein (apo)
SOD.
CCS deletion greatly reduces SOD activity in mice (Wong et al., 2000). The
phenotype of CCS -/- mice is similar to that ofSODl -/- mice with increased sensitivity
to oxidant challenge. Lack of CCS does not alter other copper chaperone-dependent
pathways, such as ceruloplasmin activation (Wong et al., 2000). A fraction of yeast CCS
is located in the mitochondrial intermembrane space with SOD (Sturtz et al., 2001).
Prohaska et al detected both CCS and SOD in purified rat brain mitochondria (Prohaska
& Gybina, 2004). Presumably, SOD in the mitochondria can scavenge superoxide
released toward the intermembrane space, whereas matrix-generated superoxide can be
disposed of by manganese-dependent superoxide dismutase (SOD2). In yeast, CCS is
necessary for copper transfer to apo-SOD under copper-limiting conditions, because the
free ionic copper content is extremely low (Rae et al, 1999). Work with CCS -/- mice
indicate a similar dependence on CCS in mammals (Wong et al., 2000).
A number of groups have independently reported elevated CCS levels in tissues of
copper-deficient mice and rats (Bertinato et al., 2003; Prohaska et al., 2003). This effect
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was not due to enhanced synthesis of CCS, as evidenced by unchanged mRNA levels in
both rats and mice. Cell culture studies indicate that elevated CCS levels in copper
limited cells is due to slower degradation by the 26S proteosome complex (Bertinato &
L'Abbe, 2003). CCS levels are not correlated with SOD levels in mammals. Higher brain
CCS levels in mice and rats have been observed even though SOD levels were unchanged
(Prohaska et al., 2003). In some tissues, such as the liver, SOD protein levels are
markedly lower following copper deficiency or deletion of CCS protein (Prohaska et al.,
2003). Cell CCS levels are affected by copper status. In fact, elevated CCS concentration
is one of the most robust cuproprotein changes following copper deprivation. Changes in
CCS concentration may be a useful way to assess copper status in humans.

Other potential copper handling and/or sensing proteins
Other copper sensing proteins have recently been discovered. Murrl directly
interacts with ATP7B (Tao et al., 2003). The loss of Murrl causes hepatic copper
overload. Murrl does not directly interact with Atoxl , suggesting that Murrl may be
required for the movement of copper to the bile from ATP7B.
Metallothionine (MT) is a low-molecular-weight cysteine-rich protein whose
function remains elusive (Coyle et al., 2002). Two isoforms of MT, MT-1 and MT-2,
may play a role in intracellular copper transfer and storage. In the perinatal liver, copper
stores are associated with MT, perhaps because of an immature biliary secretory system
and limited ceruloplasmin synthesis. Copper can induce MT synthesis, although zinc is
. more likely the physiological inducer (Coyle et al., 2002). It has been suggested that MT
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plays an important role under these conditions as well, by acting as a copper reserve
(Suzuki et al., 2002).
APP (amyloid precursor protein) is a membrane protein that contains a copper
binding site. In APP-null mice, brain copper levels are markedly elevated, compared to
those in wild-type mice (White et al., 1999). Brain zinc and iron levels are unaffected.
Conversely, in transgenic mice that overexpress APP, brain copper levels are reduced
(Maynard et al., 2002). This suggests that APP serves as a barrier to copper import in the
brain. Dietary copper supplementation can reverse both the reduction in brain copper
levels and lower the SOD activity observed in APP overexpressors (Bayer et al., 2003).

Structures of WLNP and MNKP
Both WDP and MNK have eight putative transmembrane domains, and the sixth
bears a CPC (Cysteine-Proline-Cysteine) motif which is also thought to bind to metal
ions (Lutsenko & Petris, 2003). Besides, there are six soluble N-terminal metal binding
domains each containing a conserved CXXC metal binding motif (Figure 2) (Bull & Cox,
1994). The gene that encodes WLNP is localized on chromosome 13 at loci q14.3
(Frydman et al., 1985). WLNP is 1465 amino acids. long and therefore has a molecular
weight of 159 kD.
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Figure 2. Model of Wilson Disease Protein. Domains 1-6: N-terminal metal binding
domains. Yellow and purple ribbons are the transmembrane domains.

X-ray crystallography and NMR spectroscopy have provided structures of various
metal-binding domains in different metallation states for both metallochaperones and the
partner ATPases (Achila et al., 2006; Banci et al., 2001; Banci et al., 2004; Banci &
Bertini & Cantini & Chasapis et al., 2005; Banci & Bertini & Cantini & Migliardi et al.,
2005; Banci & Bertini & Ciofi-Baffoni et al., 2005; Banci & Bertini & Cantini &
DellaMalva et al., 2006; Banci & Bertini & Cantini & Felli et al., 2006; Gitschier et al.,
1998; Rosenzweig, 2001 ). In some cases, the dynamic properties of the apo- and/or
holoproteins have been directly probed by NMR in solution (Achila et al., 2006; Banci et
al., 2001; Banci et al., 2004; Banci & Bertini & Cantini & Felli et al., 2006; Dmitriev et
al., 2006).
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Recently, Achila et al, have elucidated the apo-structure of multi-domain
construct of domains 5 and 6 together using NMR (Achila et al., 2006) (Figure 3). The
tertiary structure of these two individual domains are shown to assume a �a��a�
conformation.

A
WLN5

WLN6

B
WLN5

WLN6

Figure 3: Solution structure (ribbon representation) of apoWLNS-6. (The secondary
structure elements are indicated: �-strands are cyan and a-helices are red (Achila et al.,
2006).

24

u(l)MNK2

Cu(l)Ccc2

Ag(l)MNK4

Figure 4: Ribbon representations of the structures of (from left to right) copper(I)-bound
MNK2, copper(I)-bound Ccc2 and silver(I)-bound MNK4. The side chains of the metal
binding cysteins are shown in yellow; the metal ions are shown as pink copper(!) or green
silver(!) (Banci et al., 2004).

The yeast homologue of Wilson protein, Ccc2, contains two N-terminal binding
domains each bearing the conserved CXXC metal binding motif (Yuan et al., 1995). It is
also important to note that the structure of each domain of Ccc2 assumes a

pappap

conformation (Figure 4). Human copper chaperone, Atox 1. and its homologues found in
both eukaryotes and prokaryotes contain a single CXXC motif (Rosenzweig, 2001).

Interaction of Atox I with Wilson Protein
Human copper chaperone, Atox 1, plays a key role in copper distribution to the
secretory pathway of the cell. Insights regarding the interaction of this metallochaperone
and its target protein, WL P, have been realized from studies carried out in yeast. Atox 1
is an ortholog of yeast Atx I which is responsible for transporting copper into the Golgi
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compartment (Pufahl et al., 1997). This observation is supported by an experiment in
which Atx 1 gene is deleted in mice leading to copper accumulation and decreased
activity of secreted copper dependent enzymes such as tyrosinase (Hamza et al., 2001).
Several studies have shown evidence for physical interaction between Atox1 and WLNP
or MNKP (Achila et al., 2006; Hamza et al., 1999; Larin et al., 1999; van Dongen et

al., 2004). In a study utilizing a glutathione S - transferease-Atxl fusion, there was direct
protein - protein interaction between Atox1 and WD1-4 and that the interaction depended
on the presence of the copper ligands, CXXC in the N-terminus of Atoxl (Hamza et al.,
1999). This finding was supported by co-immunoprecipitation experiment which also
revealed that Atoxl interacts both with Wilson protein and Menk.es protein in a copper
dependent fashion (Hamza et al., 1999). A similar study to test disease-associated
mutations in the N-terminal WLNP showed a decrease in Atoxl interaction with mutated
WLNP proteins (Hamza et al., 1999). Impaired copper delivery by Atox1 is proposed to
constitute the molecular basis of Wilson disease in patients harboring these mutations
(Hamza et al., 1999).
A systemic yeast two hybrid screening of interaction between copper binding
domains showed that Atoxl interacts with MBDs 2 and 4 of WLNP. MBD4 of WLNP
showed the strongest interaction with Atoxl (van Dongen et al., 2004) suggesting that
these domains may be responsible for copper uptake from the metallochaperone before
distributing copper to the other domains. NMR studies carried our by Achila et al, also
indicates that there is complex formation between Atoxl and Wilson protein domain 4
(Achila et al., 2006). The relaxation measurement values indicate that there is a fast
exchange of the complex with the free proteins in solution. The equilibrium of this
reaction also appears to be similar to that experienced by Ccc2a and Atxl (Arnesano et
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al., 2001; Banci & Bertini & Cantini & Felli et al., 2006), a metal-mediated protein
protein interation. All the interactions between Atox 1 and single domains are found to be
weaker compared to the multidomain construct WLNP 1-4 (Larin et al., 1999).
It is logical that for the subsequent transfer of copper to take place from one
protein to another, there is a need for protein-protein interaction. Walker et al. observed
that copper transfer from Atoxl to the N-terminal WLNP results in selective shielding of
cysteines in domain 2 against labeling with a cysteine-directed probe, an observation that
is absent when free copper (without Atoxl) is added (Walker et al., 2004). They also
found that mutagenesis of WLNP domain 2 knocks out the stimulation of catalytic
activity of WLNP by the Cu-Atoxl complex but not by free copper. Based on these
observations, the authors (Walker et al., 2004) suggested that Atoxl specifically delivers
copper to domain 2 alone, at odds with protein-protein interaction experiments showing a
stronger interaction with domain 4 (Achila et al., 2006; van Dongen et al., 2004).
The authors (Walker et al., 2004) therefore proposed that the preference of Atoxl
for domain 2 may not be due to higher copper binding affinity for domain 2 nor
appropriate exposure of the metal coordinating residues but due to specific protein
protein interactions. They .state that this specific interaction is enabled by the
complementation of negatively charged patch at the surface of domain 2 and positively
charged patch on Atoxl. The authors (Walker et al., 2004) observed that copper bound
to WLNP domain 2 did not migrate to other metal binding domains; therefore, this could
support a proposal that WLPN domain 2 works as a switch allowing subsequent loading
of other sites. The initial entry site of copper from the Atoxl metallochaperone still
remains unresolved, but future experiments should compare copper delivery from Atx1 to
other domains in the full length WLNl-6 construct. Recent studies from the Rosenzweig
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laboratory showed copper transfer to each of the domains from Cu-loaded Atoxl m a
full-length six domain construct (Yatsunyk & Rosenzweig, 2007).

Mutations in Wilson Protein
A number of mutations ( over 100) in the Wilson protein gene have been identified
(http://www.medicalgenetics.med.ualberta.ca/wilson/index.php) and of particular interest,
mutations affecting the N-metal binding region significantly interfere with the ability of
Wilson protein to transport copper. Mutations in the N-terminal region include G85V in
domain 1, L492S in domain 5, Y532H in domain 5, and G591D in domain 6 (Cox et al.,
2005; Loudianos et al., 1998). Several studies have shown that domain 6 of Wilson
protein is more essential for proper function of Wilson protein. Iida et al. have shown the
importance of domain 6 by introducing domain six (i.e., WLNP lacking domains 1-5) to
yeast lacking Ccc2, a Wilson protein homologue (Iida et al., 1998). Human Wilson
protein with domain 6 but lacking other domains rescued the dying yeast. These results
indicate that all the six domains are not functionally equivalent and that WLN6 is
important for proper functioning of Wilson protein. Furthermore, Forbes et al have also
emphasized the importance of domain 6 by mutating or deleting domains 1 through 5.
Their findings show that this deletion or mutation does not significantly interfere with the
function of Wilson protein and that domain 6 alone is sufficient in yeast complementation
assays (Forbes et al., 1999). Also, it has been shown that there is impaired interaction
between Atoxl (the copper chaperone responsible for delivering copper to Wilson
protein) and Wilson protein containing the G591D mutation in domain 6 (Hamza et al.,
1999). Since copper transfer only occurs with concomitant metallochaperone-ATPase
interaction, copper delivery is thus hindered.
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There is no doubt therefore that Wilson protein domain 6 plays a significant role
in the proper functioning ofthis protein. To date there is no molecular study that has been
carried out in any of the Wilson protein disease-causing mutations and this study
therefore focuses on unraveling the molecular impairment ofthe mutant protein (G591D)
in metal binding domain 6. The results obtained could be used to understand the
important role that the MBDs play in the copper transport process. Therefore we are
expressing both the wild type and mutant (G591D) forms ofthis protein and subsequently
characterize this disease-causing mutation. Banci et al. have investigated the disease
causing mutation A629P in the sixth metal binding domain ofWLNP protein homologue,
Menkes protein (Banci & Bertini & Cantini & Migliardi et al., 2005). Their investigation
reveals that the Menkes A629P mutation makes the protein P sheet more solvent
accessible and possibly resulting in an enhanced susceptibility of ATP7A to proteolytic
+

cleavage and/or reduced capability of Cu translocation. Similar behavior may also be
observed with Wilson disease protein mutant G591D. Mutation experiments and
molecular characterization techniques must therefore be carried out in both native and
mutant forms to understand this mutation.

Objectives ofthis study
In this research, we have sub-cloned, expressed and purified the wild type form of
Wilson protein domain 6 construct for our studies, alongside the mutant form (G591D).
The other objectives of this study were to elucidate the solution NMR structure of native
and mutant WLN6. The ultimate goal of this research is to structurally characterize the
disease-causing mutation in domain 6 ofWilson protein. This will allow us to understand
29

the effects of this mutation and subsequently the copper transport mechanism inside the
cell. Also we have expressed WLN4 and WLN2 with the
This will allow us elucidate their NMR structure as well.
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CHAPTER II
EXPERIMENTAL METHODS
Materials
The ATP7B gene was obtained as a donation from Dr. Jonathan Gitlin of the
University of Washington, St Louis Missouri. All the primers were purchased from
Integrated DNA Technologies, Inc. Restriction endonucleases, relevant enzymes and
buffers were purchased from New England Biolabs Inc and Life Technologies.
Nucleotides and citric acid were purchased from Sigma Chemicals Company. Bacterial
strains and plasmids were purchased from Novagen while the QIAGEN Plasmid and
DNA Isolation Kits were purchased from QIAGEN Inc. Dimethyl sulfoxide (DMSO),
monobasic and dibasic potassium phosphates were purchased from J.T Baker Chemical
Company. Isopropyl -�-D-thiogalactopyranoside (IPTG) was purchased from !NALCO
SPA (Italy).
Sodium phosphate (monobasic and dibasic), sodium chloride, yeast extract,
dextrose and 2-(4-morpholino)-ethane sulphonic acid (MES) were purchased from Fisher
Chemicals. Deuterium oxide was purchased from Aldrich Chemicals. Coomasie plus dye
was purchased from Pierce while Bio-Rad Dye for Bradford Assay was purchased from
Bio-Rad Laboratories Inc. Bacto-Agar for making Agar plates was purchased from
DIFCO while Agarose from Gibco BRL. Kanamycin sulfate was purchased from
Calbiochem. YM3 membranes and Centricons for protein concentration were obtained
from Amicon Bioseperations, NMR tubes were purchased from WILMAD LabGlass.
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Cloning ofWLN6 gene into pET 24d
Before cloning of WLN6 into the pET 24d plasmid vector, the human cDNA
Wilson protein gene was obtained as a donation from Dr. Jonathan Gitlin ofWashington
University, St. Louis. Both forward and reverse primers for domain 6 amplification were
designed as described below.

Primer design
The primers were designed with the DNA Strider program. The sequence for the
forward primer was: 5'-GGA GGA CTA CGC ATC CAT GGA TGG CAA CAT TGA
GCT GAC-3'. This primer design included a start codon ATG which codes for
methionine and an Ncol restriction site CCATGG. The sequence of the reverse primer
was 5-GAG CGT TGG GAT CCT ACT GGG CCA GGG-3'. This design incorporated a
stop codon ACT and a unique restriction site for BamHI, GGATCC.

WLN6 amplification
The gene encoding WLN6 was amplified using the Polymerase Chain Reaction (PCR)
utilizing the designed primers. Taking into account the Guanine-Cytosine (GC) content
and the melting temperatures of the respective primers, the following written programme
was used to facilitate the polymerization activity.
-Melting temperature 95°C for 5 min.
-Annealing Temperature 65°C for 1 min.
-Extension temperature 72°C for 40 sec.
-Melting at 95°C for 40 sec.
-Annealing at 65°C for 1 min.
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-Extension at 72°C for 1 min.
Steps 4-6 were repeated 30 times. This was followed by storage in 4°C. Annealing
temperature (Tm) was calculated from the composition of the primer according to
Wallace rule (Equation).
°
[Tm (In C) = (G + C) x 4 + (A + T) x 2]

2.1

The PCR product obtained was visualized in an agarose gel electrophoresis before
purification. The product was subjected to purification using QIAquick Spin PCR
purification kit. Purified DNA was analyzed using 1% Agarose gel electrophoresis. The
gel was stained in ethidium bromide and visualized under UV light. The correct mass of
the DNA was observed.

Cloning ofWLN6
pET24d Novagen expression vector was digested using restriction enzymes Ncol and
BamHI. Purified WLN6 gene was then ligated to pET24d vector using ligase enzyme
(ligation product was named pPOWD6) at 16 °C for 10 hrs. The success of ligation was
confirmed by DNA sequencing in the laboratory of Dr. Todd Barkman at Western
Michigan University. Restriction analysis was also done to confirm ligation.

Transformation ofpPOWD6 recombinant plasmid into DH5a cells
Competent DH5a cells (200 µL each) were thawed in ice before addition of 3 µL of
dimethylsulfoxide (DMSO). 20 ng of undigested pET24d was added into the positive
control tube, a similar mass ofpPOWD6 recombinant plasmid added to another tube and
2 µL ofmilliQ water added to the negative control tube. These three tubes were placed on
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ice for 15 minutes. The cells were then heat-shocked at 42°C for 2 min. and then set on
ice for another 2 min. 1 mL of LB was finally added to each tube. These tubes were
incubated at 37°C with subsequent shaking at 250 rpm for 1 hr. After 1 hr, the tubes were
centrifuged and the pellet was resuspended in 200 µL of LB. The cells were plated on 3
different LB plates containing 30 µL/mL kanamycin. After 10 min, the plates were
incubated at 37°C for 16 hr.

Inoculation of transformed colonies
Randomly selected colonies were inoculated in 3 culture tubes containing 5 mL
LB containing 30 µL/mL kanamycin. The cultures were incubated at 37°C with shaking.
The growth of the cells was monitored by periodically measuring the optical density
(OD6oo). When the OD6oo reached 1, the culture was centrifuged and the pellet recovered.
Plasmid DNA was recovered using the Qiagen mini plasmid kit.

Analysis of recovered plasmid
The purified plasmid recovered from the above transformation was analyzed
using agarose gel electrophoresis. The plasmid was also subjected to restriction analysis
and DNA sequencing. Restriction analysis was performed by digesting the recombinant
plasmid with BamHI and Ncol. Successful clones were corresponded to the size of the
insert based on the number of base pairs. The recombinant plasmid was also. sequenced in
Dr Barkman's Laboratory of Western Michigan University, Department of Biological
Sciences.
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Transformation ofrecombinant DNA (pPOWD6) in Rosetta cells
Two aliquots of E. coli Rosetta (DE3) strain cells (200 µL each) were thawed
(Control and investigative) in ice before addition of 3 µL of dimethylsulfoxide (DMSO).
20 ng of recombinant DNA (pPOWD6) was added into the positive control tube, a
similar mass of pPOWD6 recombinant plasmid added to another tube and 2 µL of water
added to the negative control tube. These three tubes· were placed on ice for 15 min. The
cells were then heat-shocked at 42°C for 2 min. and then placed on ice for another 2 min.
1 mL of LB was finally added to each tube. These tubes were incubated at 37°C with
subsequent shaking at 250 rpm for 1 hr. After 1 hr, the cells were centrifuged down using
a microcentrifuge and resuspended in 200 µL ofLB. The cells were plated on 2 different
LB plates containing 30 µL/mL kanamycin. After 10 min., the plates were incubated at
37°C for 16 hr.

Test induction ofWLN6 protein
Some colonies observed from the previous transformation ofWLN6 with Rosetta
cells were screened for protein induction. This test set up was done to analyze the
induction levels ofWLN6 protein. A single colony from the LB plate under investigation
was inoculated in 5 mL LB treated with kanamycin sulfate (30 µg/mL). The inoculated
culture was then incubated in a shaker set at 37°C with continuous shaking at 250 rpm
until attainment of OD6oo ofapproximately 0.6.
The culture was then pelleted by centrifugation and subsequently resuspended in
50 mL ofLB medium treated with 30 µg/mL kanamycin. This culture was also incubated
in the shaker as described earlier. The OD6oo was periodically monitored using UV-Vis
spectrophotometer. When the OD6oo reached 0.6, Isopropyl-P-thiogalactopyranoside
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(IPTG) was added to an effective concentration of 1 mM. The change in OD600 was
monitored every 30 min. with successive withdrawal of 0.5 mL sample at every
measurement. Induction was continued for 4 hr. The aliquots withdrawn from each 30
min. time interval were pelleted and prepared for SDS-PAGE.
The pelleted samples were prepared for SDS-PAGE as follows: the pellets were
treated with 5 µL of loading buffer and 20 µL of water then heated to 92°C for 5 minutes.
A 15% SDS-polyacrylamide gel was prepared. The induction samples were loaded in the
wells of the gel. The gel was then run at 72 mV for 1 hr, stained with coomassie blue dye
for 6hr and then destained for a similar time. Gel drying was finally performed using a
mini gel drying unit from Invitrogen.

Production of WLN6 protein
With a positive induction from WLN6 protein test induction, a 10 L induction was
carried out starting with inoculating 5 mL of LB with a fresh, single colony transformed
in Rosetta cells. This culture was subjected to shaking at 37°C, the OD600 was also
monitored. After the OD6oo reached 0.6, the culture was transferred to another 100 mL
LB treated with 30 µg/mL kanamycin for further growth. This was now used as the
starter culture of the 10 L protein production. The 10 L LB treated with 30 µg/mL
kanamycin was set in the fermentation tank and inoculated for growth. (Microferm
fermenter, New Brunswick Scientific Co.). When the OD600 reached 0.6, protein
expression was induced with 1 mM IPTG. After 4 hr, the cells were harvested by
centrifugation at 6000 rpm for 20 min. in a SLA 3000 rotor. The pellet was stored at 20°C overnight before protein extraction.
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WLN6 protein extraction and purification

Freeze/thaw extraction
The E. coli cells with overexpressed WLN6 were frozen for 5 min. with liquid
nitrogen then allowed to thaw at room temperature successively for 3 cycles. The pellet
was then resuspended in 240 mL (24 mL per liter of culture) extraction buffer (20 mM
MES/Na; 1 mM EDTA, 10 mM Dithiothreitol (DTT), pH 6). The suspension was
agitated in ice for 1 hr. Non-soluble portions of the cells were pelleted by centrifugation
at 6000g for 15 min. at 4°C. The protein containing supernatant was decanted from the
pellet and filtered through a 0.22 µM filter in preparation for anion-exchange
chromatography. Pre and post-filtration samples were taken for later Bio-Rad analysis.
WLN6 protein was purified in two chromatographic steps: anion exchange
chromatography (DEAE column) and gel filtration.

Anion exchange chromatography
An Amersham Pharmacia Biotech DEAE sepharose fast-flow chromatographic
column (Pharmacia, 2.6 cm x 13 cm, 69 mL) was packed with DEAE Sepharose resin to
yield a total volume of approximately 70 mL). The column was then equilibrated with
buffer A (20 mM MES/Na, 1 mM EDTA, 10 mM DTT, pH 6). The filtered supernatant
from the freeze-thaw extraction step was then loaded onto the column. The first 50 mL of
eluent from the column was collected and named 'flowthrough 1' while the next 190 mL
was collected and named 'flowthrough 2'. The unbound protein was eluted from the
column using 2 column volumes wash of Buffer A and this was collected and named
'column wash'. The protein bound onto the column was eluted using a salt gradient over
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3 column volumes. A program was designed to elute the proteins with a mixture of buffer
A (20 mM MES/Na, 1 mM EDTA, 10 mM DTT, pH 6) and Buffer B (20 mM MES/Na, 1
mM EDTA, 1 M NaCl, 10 mM EDTA, pH 6) at an increasing salt gradient until a
maximum salt concentration of 50%. The eluent was collected in 95 fractions of 2.5 mL
each. The Bio-Rad protein assay was performed for every fraction. The fractions
containing WLN6 protein were confirmed by 15% SDS-PAGE. The fractions containing
WLN6 protein were combined and concentrated down to 2 mL with an Amicon device
using a YM3 membrane and pressurized nitrogen.

Gel filtration chromatography
WLN6 protein was separated from higher molecular weight impurities with size
exclusion chromatography (gel filtration). First, a pre-packed Amersham Pharmacia
Superdex-75 26/60 gel filtration column was washed with one column volume of filtered
water at a flow rate of 2.6 mL/min. The column was then equilibrated with two column
volumes of buffer (20 mM MES/Na, 150 mM NaCl, 10 mM DTT, pH 6). The
concentrated protein solution containing WLN6 protein was loaded into the injection
loop. A large superdex gel filtration computer programme was activated to inject the
sample into the column with an elution volume 1.5 column volumes. The eluent was
collected in 94 fractionation tubes each containing 5.2 mL fractions. The Bio-Rad assay
was used to test for protein containing fractions while 15% SDS-PAGE was performed to
analyze the purity of the fractions containing WLN6 protein. All the pure fractions were
pooled together and concentrated on Amicon device fitted with a YM3 membrane to 2
mL. The sample was then stored at -80°C.
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Sample preparation for Nuclear Magnetic Resonance
2 mL of WLN6 protein pure stock solution (0.2 mM) was aliquoted, reduced by
addition of excess DTT and degassed with nitrogen gas. The sample was then transferred
to a nitrogen atmosphere and vacuum atmosphere glove box. The sample was then
exchanged to 100 mM sodium phosphate buffer, pH 7.2, using an Amicon device fitted
with a YM3 membrane. The WLN6 protein solution was then finally concentrated down
to 540 uL. This volume was pipetted into a microcentrifuge tube to which 60 µL of D2 0
was added. The total volume of the sample was 600 uL (10% D2 0) with a concentration
of 0.5 mM. The sample concentration was estimated with the Bio-Rad assay. The
prepared 0.5 mM WLNP protein sample was transferred to an NMR tube, capped with a
septum cap and brought out of the anaerobic chamber. The sample was the shipped to
Italy at the Centre for Magnetic Resonance, University of Florence.

Isotopic labeling of WLN6 protein
Isotopic labeling of proteins is important in solving solution structures using
NMR. In two dimensional and three dimensional NMR ·studies, proteins are labeled with
C-13 and/or N-15. For uniform labeling of WLN6 protein with

15

N and

1

3C,

the same

expression vector used for overexpressing unlabelled WLN6 was used. The cells were
incubated in minimal growth media (enriched phosphate buffer, pH 7.2). Just prior to
labeling, a test induction for WLN6 protein was carried out in minimal media to analyze
the protein expression levels in this media. 15 N labeled WLN6 protein was produced by
growing Rosetta cells with pPOWD6 recombinant plasmid in minimal media
supplemented with 15 Nl4Cl as a 15 N nitrogen source. 1 L of minimal media contains 6 g
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of Na2HP04, 3 g of KH2PO4, 0.5 g NaCl, 1 g of 15 N�Cl, 0.4% dextrose sugar, 2 mM
MgSO4, 0.1 mM CaCh, 2 mL of 0.2% thiamin and 30µg/mL kanamycin sulfate.
The procedure for 15 N WLN6 protein expression was carried out as follows: A 5
ml LB culture treated in 30 µg/mL kanamycin was inoculated with Rosetta
DE3/pPOWD6 plasmid colony and the cells were incubated at 37°C. When the OD600 of
the medium was 0.8, the bacterial pellet was isolated and resuspended in the complete
15

N minimal media for further incubation. The cell culture was grown in a 2 L flask and

the growth monitored with periodic measurement of OD at 600 nm. After the OD600
reached 0.6, protein expression was induced in 1 mM IPTG. The cells were harvested 6
hr later by centrifugation. The

15

N labeled protein was recovered by freeze-thaw

extraction, anion exchange chromatography and finally gel filtration as outlined in the
purification protocol explained earlier in chapter 2. This protein was also prepared for
NMR studies as and shopped to CERM, Italy for NMR analysis. The 15 N and 13C WLN6
protein was produced using a similar procedure but ensuring that the minimal growth
media contained 1 g of 15 NH4Cl per liter and 2 g of 13 C glucose per liter.

Determination of WLN6 protein concentration
Protein concentration of WLN6 protein was determined by a combination of
Bradford Assay (Bio-Rad) and UV-Vis technique. In Bio-Rad assay, immunoglobulin G
(JgG) standard protein concentrations were prepared (ranging from 1.51 to 21.14 µg/mL).
The corresponding UV absorbance at 595 nm of each IgG standard prepared was
determined and the absorbance value was plotted as a function of lgG concentration. The
resultant calibration curve was used to determine the concentration of pure WLN6
protein.
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Site-directed mutagenesis of WLN6 protein
In order to compare the wildtype WLN6 protein with the mutant WLN6(G591D),
mutagenesis was performed on the recombinant vector (pPOWD6). The Strategene
Quick-change site-directed mutagenesis kit was used to introduce the G591D mutation.
The sequence of the forward mutagenic primer was : 5' CTC ACG AGG ACA AAT
GAC ATC ACT TAT GCC TCC G - 3' and the sequence of the reverse mutagenic
primer was : 5' CGG AGG CAT AAG TGA TGI CAT TTG TCC TCG TGA G 3'(underline indicates the point at which mutation was introduced). The following
reagents were mixed in a 1 mL microcentrifuge tube: 30.9 µL double-deionized water,
5.0 µL Strategene l 0x reaction buffer, 1.0 µL (20 ng) recombinant pJK1-62(1c) vector,
6.0 µL (125 ng) forward primer, 6.1 µL(125 ng) reverse primer, 1.0 µL Strategene dNTP
mix and 1.0 µL Strategene PfuTurbo DNA polymerase. The solution was overlaid with
30 µL of mineral oil and subjected to the PCR.

Digestion of DNA by Dpnl enzyme
After the reaction mixture was subjected to several PCR cycles, the non-mutated
parental DNA was digested with Dpnl restriction enzyme (lOU/µL). 1.0 µL of the
restriction enzyme was added to the PCR product. The reaction mixture was then
centrifuged at 10,000 rpm for 1 minute in an eppendorf microcentrifuge. The mixture was
then incubated at 37°C for 1 hr.
The mutated plasmid from the reaction above was transformed into DH5a E. coli
cells according to the transformation protocol outlined earlier. The transformation
product was plated on LB agar plates treated with 30 µg/mL kanamycin and incubated in
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37°C overnight. A few colonies obtained from the transformation were inoculated in a
starter culture, 5 mL which was then transferred to a 100 mL LB culture for plasmid
recovery. The pure plasmid, pPOWD6-G591 was recovered after isolation and
purification using Qiagen mini elute protocol.

Transformation and protein expression
The purified mutant plasmid (pPOWD6-G591D) was transformed into Rosetta
(DE3) cells using the same methods described for wildtype pPOWD6 transformation.
WLN6 (G591D) protein expression was studied via a time-course induction test in 1 mM
IPTG (a synthetic mimic of the natural inducer, 1, 6- allolactose which binds to the lac
repressor) on the 100 mL LB culture inoculated with mutated WLN6 plasmid (WLN6G591D). 500 µL aliquots of samples were withdrawn every 30 min. and centrifuged for
15% SDS-PAGE induction analysis. After 4 hr of induction, the culture was harvested by
centrifugation at 6000 x g for 15 min. The cells were. stored in -20°C overnight for
WLN6(G591D) protein extraction. The centrifuged aliquoted samples were analyzed by
SDS-PAGE for induction.

Freeze/Thaw extraction of WLN6(G591D)
Freeze/Thaw extraction buffer was 20 mM MES/Na, 1 mM EDTA, 10 mM DTT,
pH 6. The WLN6(G591D) protein bacterial pellets were resuspended in the freeze-thaw
extraction buffer (24 mL of buffer per liter of induction culture). The suspension was
gently agitated in ice for 1 hr. The non-soluble portions of the cells were pelleted by
centrifugation at 6000 g for 15 minutes. Both the supernatant and the pellet were tested
with analytical SDS-PAGE for the mutant WLN6-G591D protein. Since the mutant
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protein was absent in the supernatant and present in the bacterial pellets, another
extraction technique was used to solubilize the protein.

Extraction of WLN6(G591D) by sonication
E. coli Rosetta (DE3) cells containing WLN6(G591D) protein were resuspended
in the freeze/thaw extraction buffer, pH 6, and vortexed for 3 min. The suspension was
then subjected to sonication for 15 min. (five 1 min. pulses at 3 min. intervals). After
sonication the suspension was subjected to continuous shaking at 70 rpm for 2 hrs. The
extract was centrifuged at 6000xg for 15 min. Both the supernatant and the pellet were
saved and analyzed for WLN6(G591D) protein with 15% SDS-PAGE.

Extraction of WLN6(G591D) by commercial detergent
BugBuster® protein· extraction reagent is formulated for the gentle disruption of
the cell wall of E. coli to liberate recombinant proteins. It provides a simple, rapid, low
cost alternative to mechanical methods such as French press or sonication for releasing
expressed target protein in preparation for purification or other applications. The
proprietary formulation utilizes a detergent mix that is capable of cell wall perforation
without denaturing protein.
The bacterial pellet from the sonication procedure was res.uspended in 12.5 mL
BugBuster® reagent (5 mL per gram of cells). To reduce the viscosity of the lysate, 1 µL
(25 U) benzonase nuclease per ml BugBuster® reagent was added into the suspension.
12.5 µL of protease inhibitor (1 µL per mL of BugBuster® reagent) was also added to the
mixture. The cell suspension was incubated on a shaking platform at 50 rpm for 30 min at
room temperature. Insoluble cell debris was removed by centrifugation at 16,000xg for
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20 min. at 4°C. A 15% SDS-PAGE was performed on samples from both the supernatant
and the pellet to determine the extraction efficiency and protein solubility in the reagent.
The pellet and supernatant were stored at -20°C.

Solubilization of WLN6(G591D by guanidinium chloride
Because the mutant WLN6(G591D) was still in the pellet (15% SDS-PAGE) even
after a series of extractions with different techniques,· complete solubilization of bacterial
cells was necessary. The test protocol for this extraction was developed as follows: 2.5 g
of bacterial pellet containing WLN6(G591D) was resuspended in 10 mL of 8 M
guanidinium chloride (2.5 mL/gram of pellet). The suspension was placed on ice and
gently agitated until solubilization was complete. The solubilized suspension was
centrifuged at 12,000xg for 30 min. and the supernatant was isolated. The supernatant
was slowly diluted in freeze-thaw extraction buffer (20 mM MES/Na, pH 6, 0.1 mM
EDTA, 10mM DTT) 40 fold. This mixture was filtered through a 0.22 µm protein filter
membrane. The filtered extract was then concentrated to 10 mL using an Amicon device
fitted with a YM3 membrane. An analytical sample of this extraction process was
subjected to SDS-PAGE.

Extraction of mutant WLN6(G591D) with various buffers
Since the solubility of mutant WLN6(G591D) was low (WLN6(G591D) was poorly
extracted), different buffers at different conditions were prepared to optimize the
extraction conditions for the mutant protein. Below is a list of solutions that were
prepared to enhance the mutant protein extraction.
✓ 20 mM MES/Na, pH 5.5, 0.lmM EDTA
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✓ 20 rnM MES/Na, pH 6.5, 0.1 rnM EDTA
✓ 20 mM MES/Na, pH 6.2, 0.1 mM EDTA, 100 rnM NaCl
✓ Bugbuster® Extraction Reagent ( Tris/Cl, pH 7.2)
✓ 8 M Guanidine Hydrogen Chloride, pH 6
A test extraction was carried out in 5 different microcentrifuge tubes. First, the
same amount (0.1 g) of bacterial pellet containing mutant WLN6(G591D) protein was
transferred to all the 5 microcentrifuge tubes. 20 µL of each reagent was added to the
corresponding pellet. Pellet in each tube was resuspended in the buffer after which the
suspensions were vortexed for 3 minutes each. The tubes were then placed in a slow
shaker for 10 min. and then centrifuged in a microcentrifuge for 2 min at 14,000 rpm.
The supernatant in each tube was saved and analyzed with SDS-PAGE.

Site-directed mutagenesis of G591D in the two domain construct WLN5-6
Since _all attempts to extract mutant WLN6(G591D) protein were not successful,
we decided to attempt the same mutation (G591D) in a two domain construct, WLN5-6.
Our hypothesis was that the same mutation in WLN5-6 would enhance the stability of the
mutant protein. This hypothesis was based on the earlier experience with WLN5-6.
Mutagenesis was performed on the recombinant vector pDAWD5-6. The
Strategene Quick-Change Site-Directed Mutagenesis kit was used to introduce the
G591D mutation. The sequence of the forward mutagenic primer was: 5' CAA CCA
GAG CCA TGG CAC CGC AGA AG- 3' and the sequence of the reverse mutagenic
primer was: 5' CGG AGG CAT AAG TGA TGI CAT TTG TCC TCG TGA G - 3'
(underline indicates the point at which mutation was introduced). Mutagenesis was
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performed using Strategene kit following the Strategene protocol. The reaction mixture
was finally subjected to the PCR.
After the reaction mixture was subjected to several PCR cycles, the non-mutated
parental DNA was digested with Dpnl restriction enzyme (l0U/µL). The mutated
plasmid from the reaction above was transformed into XL-Gold ultracompetent cells as
outlined below. The plates were then incubated overnight at 37°C. The colonies obtained
from transformation were inoculated in LB and the plasmid recovered as using Qiagen
midi prep procedure outlined in the Qiagen protocol. The plasmid was confirmed by
agarose

gel

electrophoresis

and

the

concentration . determined

by

UV-Vis

spectrophotometer. This was done by measuring the absorbance at 260 and 280 nm
wavelengths respectively. The purified plasmid (800 ng of pWD5-6(G591D) was then
availed for sequencing in Dr. Barkman's Lab. 2 µL of the plasmid was transformed in
Rosetta (DE3) cells for induction test using the same methods described earlier. Protein
expression was studied via a time-course induction test using 1 mM IPTG on the 100 mL
LB culture inoculated with mutant WLN5-6 plasmid (pWD5-6-G591D). 250 uL aliquots
of samples were withdrawn every 30 minutes and centrifuged to be analyzed for
induction. After 4 hrs of induction, the culture was harvested by centrifugation at 6000xg
for 15 min. The cells were stored in -20°C overnight for WLN5-6 protein extraction. The
centrifuged aliquoted samples were analyzed by SDS-PAGE for induction.

Extraction of mutant WLN5-6(G591D)
Protein extraction was done according to the procedure previously described
using freeze-thaw extraction buffer (20 mM MES/Na, pH 6, 0.1 mM EDTA, 10 mM
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DTT). Also BugBuster® test extraction was carried out using similar protocol explained
earlier. These two extraction methods were compared by 15% SDS-PAGE.

Ligation independent cloning (LIC)
Due to low yields of WLN5-6(G591D), we decided to clone the mutant plasmid
as a fusion protein following the protocols described by Novagen. Fusion proteins are
known to improve protein solubility and also enhance protein purification. The sense
primer was designed to encode the last four amino acids of the enterokinase (EK)
cleavage site plus the C-terminal flanking amino acid Met. The sequence of the GST
fusion forward primer was: 5'- GAC GAC GAC AAG ATG GCA CCG CAG AAG
TGC TTC TTA CAG - 3' and the sequence for the GST fusion reverse primer was: 5'
GAG GAG AAG CCC GGT CTA CTG GGC CAG GGA AGC ATG AAA G- 3'. The
forward primers for the thioredoxin fusion protein was: 5'- GGT ATT GAG GGT CGC
ATG GCA CCG CAG AAG TGC TTC TTA CAG -3' while the reverse primer for
thioredoxin fusion protein was: 5'- AGA GGA GAG TTA GAG CCC TAC TGG GCC
AGG GAA GCA TGA AAG - 3'.
Two PCR tubes were set with the following: In the first tube 58 µL H20, 10 µL
thermopol buffer (lOx), 10 µL 2 mM dNTP mix, 10 µL Ek/LIC WLN5 Fwd primer (10
µM), 10 µL Ek/LIC WLN6 reverse primer (10 µM), 2 µL template (pWD56-G591D),
and 0.9 µL DNA polymerase (Deep Vent). This mixture was overlaid with 40 µL mineral
oil. In the second tube the following reagents were mixed together: 58 µL H20, 10 µL
thermopol buffer (l0x), 10 µL 2mM dNTP mix, 10 µL Xa/LIC WLN5 Fwd primer (10
µM), 10 µL Xa/LIC WLN6 reverse primer( 10 µM), 2 µL template(pWD56-G591D), and
0.9 µL DNA polymerase (Deep Vent). The two tubes were set on a PCR machine and the
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desired DNA piece amplified using the following PCR program: Melting temperature of
95°C for 5 min, annealing temperature of 65°C for 1 minute, extension temperature of
72°C for 40 sec, melting at 95°C for 40 sec, annealing of at 65°C for 1 min and Extension
at 72°C for 1 min. The last 3 cycles were repeated 27 times.
After the DNA amplification, an agarose gel electrophoresis was run to ascertain
the presence of the DNA piece. The PCR product was then purified using Qiagen mini
elute protocol. The purified product was also quantified by agarose gel electrophoresis
T4 DNA polymerase treatment of target insert
T4 DNA polymerase treatment of the insert was performed to generate
compatible overhangs on the insert. The following components were assembled in a PCR
tube: 10 µL purified PCR product, 2 µL T4 DNA polymerase buffer (lOx), 2 µL 25 mM
dATP, 1 µL 100 mM DTT 0.4 µL T4 DNA polymerase (UC-qualified) and 4.6 µL
nuclease-free water. The total volume of the components was 20 µL. The reaction was
started by adding the enzyme and stirring with the pipette tip for 2 minutes. The mixture
was then incubated at 22°C for 30 min. Finally the temperature was raised to 75°C for 20
min. to inactivate the enzyme.
Annealing the vector and the treated insert (Ek/LIC WLN5-6(G591D)
Annealing of the pET41 LIC vector and the treated insert (Ek/LIC WLN56(G591D) was done by assembling the following components in a sterile PCR tube: 1 µL
Ek/LIC vector (pET 41) and 2 µL T4 DNA polymerase-treated Ek/LIC WLN5-6(G591D)
insert. These were incubated at 22°C for 5 min then 1 µL 25 mM EDTA was added to the
mixture with stirring followed by incubation at 22°C for 5 min. Annealing continued for

48

1 hr. The same process was performed for Xa/LIC WLN5-6(G591) insert. However, the
annealing vector used was pET32 instead of pET41.
The DNA clones produced were sequenced in Dr. Barkmans Lab. 20 ng of both
plasmids (pEk/LIC WLN5-6(G591D) & pXa/LIC WLN5-6(G591D) were transformed in
Nova Blue Giga Singles TM competent cells according to the protocol in the Novagen kit.
The transformation products were plated on LB plates treated with kanamycin (30
µg/mL, for pEk/LIC WLN5-6(G591D) and/or ampicillin (100 µg/mL, for pXa/LIC
WLN5-6(G591D). The plates were incubated at (37°C) for 24 hr.
Some of the observed colonies were inoculated in different 5 mL LB treated with
30 µg/mL kanamycin or 100 µg/mL ampicillin. The cultures were grown to a high
density and transferred to a 100 mL culture for plasmid isolation. The cultures were
harvested by centrifugation followed by plasmid isolation and purification according to
the Qiagen Midi-Prep protocol explained earlier. Some of the plasmid was submitted for
sequencing in Dr. Barkmans Lab, but the sequencing reaction repeatedly yielded
overlapping products.

Later, it was determined by sequencing at Retrogen that an

insertion product within the gene occurred. This was not determined prior to subsequent
experiments and expression studies of this construct. Nonetheless, valuable information
was learned about expression and purification of the mutant protein. Now, studies are
being performed on the corrected sequence; however, these studies are not described in
this thesis.
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Transformation of LIC plasmids (uncorrected sequence -vide supra)
Both plasmids were transformed in Rosetta (DE3) pLys cells. The product was
plated on LB in 30 µg/mL kanamycin and incubated overnight at 37°C. Some of the
positive colonies observed on the plates were inoculated and tested for protein induction.
The induction was done with addition of 1 mM IPTG and this was continued for 4 hrs.
The bacterial pellets were harvested by centrifugation at 6000xg and stored at -20 °C. The
samples withdrawn at each hr interval were analyzed by SDS-PAGE.
Restriction analysis
To verify cloning, restriction analysis was carried out by assembling the following
reagents in one tube: 10 µL of purified plasmid (pEk/LIC WLN5-6(G591D) or pXa/LIC
WLN5-6(G591D), 0.8 µL BglII, 0.2 µL BamHI, 0.2 µL, l0x Bovine Serum Albumin
(100 mg/mL)), 0.2 µL BamHl buffer and 8.8 µL H2 0. This mixture was incubated at
37°C for 12 hr. An analytical sample was run in agarose gel to confirm digestion.

Extraction and purification of fusion proteins (GST-WLN5-6(G591D) and Thioredoxin
WLN5-6(G591D)
The fusion mutant protein-containing bacterial pellets were thawed and
resuspended in BugBuster® extraction buffer. The extraction of the fusion proteins was
done with BugBuster® according to the protocol explained in chapter two. The extracts
(supernatant) were tested for the respective mutant fusion proteins (GST fusion and
Thioredoxin fusion) by estimation of the combined masses (fusion tag and mutant
protein) on an SDS-PAGE. Solubilization of bacterial pellets containing GST and
Thioredoxin-WLN5-6(G591D) proteins were done in 6 M guanidinium chloride for total
protein recovery. GST fusion protein, GST-WLN5-6(G591D)
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was then exchanged

slowly in GST binding buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 1.8 mM
KH2PO4, pH 7.3) using an Amicon device fitted with a YM3 membrane. This mutant
protein was then subjected to affinity purification step - GST Column purification. The
GST column was pre-packed from Amersham Inc. with glutathione resin. The column
was integrated to the Amersham FPLC machine and equilibrated with 2 column volumes
(40 mL) of GST binding buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2 HPO4, 1.8 mM
KH2PO4, pH 7.3). The sample was injected to the GST column. This was followed by 2
column volumes wash of the column with OST-binding buffer and then isocratic elution
with 5 column volumes (100 mL) of GST elution buffer (50 mM Tris, 100 mM reduced
glutathione, pH 8). During elution, fractions were collected in tubes and analyzed by the
Bio-Rad assay and SDS-PAGE for protein and mutant fusion protein (GST-WLN56(G591D) respectively. Thioredoxin fusion protein extract, Thio-WLN5-6(G591D), was
also loaded onto the Histidine Tag column after equilibration with 2 column volumes of
HisTag binding buffer (20 mM sodium phosphate buffer, 0.5 M NaCl, 20 mM Imidazole,
pH 7.4). The protein was then eluted with 3 column volumes (60 mL) of HisTag elution
buffer (20 mM sodium phosphate buffer, 0.5 M NaCl, 500 mM Imidazole, pH 7.4). The
elution volume was collected in different 2 mL fractions and analyzed using Bio-Rad
assay and SDS-PAGE.
Enterokinase cleavage of GST-WLN5-6(G591D)
A test cleavage of the GST tag from the mutant protein was carried out by
enterokinase cleavage enzyme (1U) by assembling the following in a microcentrifuge
tube: 13 µL (50 µg) of GST fusion protein from GST purification (Ek/LIC WD56G591D), 13 µL of lx Enterokinase cleavage buffer, and 1 µL of porcine enterokinase
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(lU). This mixture was incubated at 25°C for 18 hr. Samples (cleaved and uncleaved)
were analyzed using SDS-PAGE. Similar conditions employed for the test cleavage were
duplicated for the entire 10 mL volume (3.5 µg/mL) of OST-purified protein sample. All
samples were analyzed by15% SDS-PAGE.

Factor Xa cleavage ofthioredoxin-WLN5-6(G591D)
Cleavage of the thioredoxin fusion tag from the mutant protein was carried out by
Factor Xa cleavage enzyme by assembling the following reagents in a microcentrifuge
tube: 13 µL (50 ug) ofthioredoxin fusion protein from HisTag purification (Thio-WLN56(G591D), 13 uL of lX Factor Xa cleavage buffer and 1 µL of Factor Xa enzyme (1U).
This mixture was incubated at 25°C for 18 hr. Samples (cleaved and uncleaved) were
analyzed by SDS-PAGE. Similar conditions employed for the test cleavage were
duplicated for the entire volume (7.5 mL) of His-Tag-purified protein sample with
adjusted quantity ratios ofreagents.

Transformation ofmWD4-Avitag in Rosetta TM (DE3) cells
Single molecule studies of WLN4 are being carried out in the laboratory of
Professor Peng Chen at Cornell University. Using our expression system, Dr. Chen's
laboratory added an Avitag to the protein. Details of this process and the sequence can
be obtained in writing from Professor Chen. In order to purify this protein, 1 µL of the
mWD4-Avitag labeled sample (48.9. ng/µL) was transformed in Rosetta™(DE3) cells.
The cells were plated on LB containing 30 µg/mL kanamycin. The plates were incubated
at 37°C overnight.
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Protein induction (mWD4-Avitag)
5 mL LB (containing 30 µg/mL) in a culture tube was inoculated with a colony
from the previous transformation. The culture was grown in a shaker at 37°C and the
OD6oo was monitored. The 5 mL culture was then transferred to a 1 L LB treated with 30
µg/mL kanamycin. The OD6oo was monitored until 0.6 after which induction was
initiated in 1 mM IPTG .The induction process was continued for 4 hr with successive
withdrawal of a 500 µL sample after every 1 hr. After induction was complete, the
bacterial cells were harvested by centrifugation at 6000xg for 20 min. The samples were
subjected to SDS-PAGE for analysis. The pellets were stored at -20°C.

Extraction and purification of mWD4- Avitag

Freeze/thaw extraction
The bacterial cells containing mWD4-Avitag protein were subjected to 3 cycles of
freezing and thawing in liquid nitrogen and water respectively. 25 mL of Freeze/thaw
extraction buffer (20mM MES/Na, lOmM DTT, l mM EDTA, pH 6) was used to
resuspend the thawed cells. The suspension was shaken (100 rpm) for 30 min (to enhance
protein extraction). mWD4-Avitag protein was finally recovered in the supernatant after
centrifugation at 6000xg for 20 min. The supernatant was filtered through a 0.22 µm
filter membrane.
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Anion exchange chromatography
Buffers were prepared and filtered in a 0.22 µm filter. The buffer compositions were
as shown below:
❖ Low salt buffer - 20mM MES/Na, pH 6, 1 0mM DTT
❖ High Salt buffer - 20mM MES/Na, pH 6, l0mM DTT, IM NaCl
❖ Column used: DEAE Sepharose
mWD4-Avitag sample was loaded onto the DEAE column integrated with FPLC. The
sample was eluted with a linear salt gradient. The fractions containing mWD4-Avitag
were collected in tubes. The fractions containing the protein (mWD4-Avitag) were
analyzed with SDS-PAGE.

Sample concentration and gel filtration
The DEAE fractions containing mWD4-Avitag were collected and concentrated using a
YM3 membrane to a final volume of 3 mL. This volume was loaded onto a large
superdex column (330 mL Column Volume) for further purification and separation. Pure
fractions were collected and analyzed by SDS-PAGE.

· Mass Spectroscopy (ESI-MS) ofmWD4-Avitag
A pure protein sample of the m-WD4 Avitag protein was submitted to the
University of Michigan, Protein Structure Facility for Mass spectrometry. 200 µL of gel
filtration sample (fraction 39) was diluted with water 3 fold. The volume (600 µL) was
concentrated to 50 µL using microcon fitted with YM3 membrane. The composition of
the final sample submitted for mass spectrometry was as follows: Buffer components: 6
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mM MES/ Na, 50 mM NaCl, 3 mM DTT, pH 7, Volume: 40 uL and Concentration: 0.49
mM.

NMR spectroscopy
The. strategy used for the determination of solution NMR structure of WLN6
involved careful preparation of unlabeled and labeled protein solutions, spectra
acquisition, spins system and sequential resonance assignment, collection of
conformational constraints and calculation of the 3D structure. Spin system resonance
assignment identified which proton resonance belonged to which residue type while
sequential resonance assignment showed which proton belonged to which residue in the
WLN5-6 protein sequence. The calculated NOE and J-coupling NMR constraints were
used to identify which protons were close in space and what the torsion angles were. The
structure calculated represents conformation(s) consistent with all the NOE, J-coupling
and other constrains. The reported structure is a mean of an ensemble of 20 lowest energy
structures of the protein calculated from the collected data. All NMR experiments were
performed at the Magnetic Resonance Center (CERM), University of Florence, Italy.
WLN6 NMR spectra were acquired on Avance 900, 800, 600 and 500 Bruker
Spectrometers operated at a proton nominal frequency of 900.13 MHz, 800.13 MHz,
600.13 MHz and 500.13 MHz respectively. All 2D and 3D spectra were collected at 298
K, processed using the standard Bruker software (XWINNMR) and analyzed using the
CARA program. 1H, 15N-Heteronuclear single quantum coherence (HSQC) experiment.
The 1 H, 15N-HSQC experiment is a two dimensional (2D) experiment that depends upon
scalar coupling between the amide nitrogens and their attached protons. Each of the
naturally occurring amino acids (except proline) gives one resonance from 1 H, 15N-HSQC
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spectrum which corresponds to the N-H amide group. The spectrum contains the signal
of the HN protons in the protein backbone and since there is only one backbone HN per
amino acid, each HSQC signal represent one single amino acid.

Resonance assignment and structural restraints
1H - 1H distances and the dihedral angles were dete�ined through Nuclear Overhauser
Effect spectroscopy (NOESY) and HNHA experiments. H-bond constraints were
obtained using transverse relaxation optimized spectroscopy (TROSY) version of the
long range HNCO experiment at a magnetic field of 700 MHz. Relaxation experiments ·
were performed on a Bruker Avance 600 MHz NMR at 298 K. The WLN6 structure and
folding was calculated from the constraints derived from these experiments.

Relaxation rate measurements
The relaxation experiments were performed on Bruker Avance 600 MHz or 500 MHz
spectrometers at 298 K. 15N R1, R2, and steady-state heteronuclear 1H,15N NOEs were
measured with pulse sequences as described by Farrow et al. (Farrow et al., 1995).
Integration of cross peaks for 15N R1, R2, and 1H, 15N NOEs spectra was performed by
using the standard routine of the XWINNMR program. Relaxation rates R1 and R2 and
heteronuclear NOE values were determined following a standard procedure as reported
previously (Arnesano et al., 2001). The experimental relaxation rates were used to map
the spectral density function values, J(£sH), J(£sN), Jeff(0), following a procedure
available in literature (Peng & Wagner, 1992), in order to investigate the backbone
motions. An estimate of the overall rotational correlation time was derived from the
measured R 2/R1 ratio by using a standard procedure (for example, see (Amesano et al.,
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2001).

Circular Dichroism
A circular dichroism (CD) experiment was used to probe helicity of WLN56(G591D). A WLN5-6(G591D) solution was prepared by reduction in 10 mM DTT and
then exchanging in 50 mM sodium phosphate, pH 7.2 buffer under anaerobic conditions.
The final sample had a concentration of 12.5 µM WLN5-6(G591D). A 10 mm jacketed
cell was thoroughly cleaned and dried before samples were introduced. The
spectropolarimeter was attached to a nitrogen generator. Temperature was set and
maintained at 25°C by running water through a jacketed cell. After 1 hr of incubation the
samples were scanned at a speed of, starting with the blank, at a rate of 20 nm per second
over the far UV range of 190 nm to 300 nm. CD spectra were collected on a J-80
spectropolarimeter (JASCO-J-80, Japan) fitted with a 150 W Xenon lamp. The spectrum
was corrected for background noise.
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CHAPTER III
RESULTS
Cloning ofWLN6
The portion of the WLNP gene encoding for the N-terminal metal binding
domains 6 was amplified from a human cDNA plasmid encoding full length WLNP
through 28 PCR cycles in a MiniCycle using Deep Vent DNA polymerase (New England
Biolabs). PCR products were purified, double digested with restriction endonucleases
Ncol and BamHl then cloned into an E. coli expression vector, pET24d. The
recombinant plasmid was transformed in DH5a cells and the recombinant plasmid was
isolated and purified (see Fig 5)

6 kb
4 kb
2 kb
1.5 kb
I kb
0.5 kb

Figure 5. Agarose gel electrophoresis ofWLN6 recombinant pure plasmid on a 1 %
agarose gel. Lanel, is the 1 kb marker, lanes 2 & 3 are recombinant plasmid (~5,500b p)

Cloning was verified by sequencing of the gene in Dr. Barkman's lab and also by
restriction analysis of the recovered plasmid employing BamHI and Ncol restriction
enzymes. The sequence of the insert matched with the native sequence for this portion of
the gene. The alignment was done using the DNA Strider program. Band representing a
fragment ~250 base pairs (bp) was observed on a 1 % agarose electrophoresis gel of the
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doubly digested recombinant plasmid. This was a confirmation that WLN6 gene was
successfully inserted into the expression vector, pET24d.

Induction ofWLN6 in LB media
The time course induction of WLN6 protein was done to test the efficiency of
WLN6 protein expression in LB media containing 30 µg/L of kanamycin. The
recombinant plasmid (pPOWD6) was transformed into E. coli Rosetta (DE3) cells and
·induced for WLN6 protein expression in LB medium using IPTG. Kanamycin was used
to select for cells transformed with the recombinant plasmid because the plasmid
contained genes for kanamycin resistance. The growth of the cells was monitored by
measuring optical density at 600 nm (OD6oo). WLN6 expression was induced at OD600 of
0.6 by addition of 1 mM IPTG. IPTG binds and inactivates the lac operon repressor and
therefore induce WLN6 gene transcription by RNA polymerase. The OD600 was measured
periodically until completion of protein induction (~ 4 hrs). The samples withdrawn in
every time interval were centrifuged and analyzed on SDS-PAGE gel for WLN6
induction. The loading on SDS-PAGE was normalized by the OD6oo reading using
equation 3.1.
OD60o at time Ox 15 µl
0D600 at time ti

3.1

The results showed a steady increase in cell density with time (this is indicated by
subsequent increase in OD6oo) (Table 4). The bacterial cells growth was not hampered by
addition of IPTG, instead there was a gradual growth of cells in the nutrient medium
(LB). The normalized loading on SDS-PAGE showed increase in intensity, with time, of
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a protein band of ~7.5 kDa believed to be of WLN6 protein (Figure 6). This shows that
WL 6 induction and expression was successful. A 10 L batch was planned to produce
more protein.

Time(min)
0
30
60
90
120
150
180
210
240

Optical Density (OD6oo)
0.6341
1.0530
1.3780
1.6060
1.7057
1.8262
1.9675
2.0161
2.1310

Normalized loading vol.(µL)
15.00
9.030
6.900
5.920
5.570
5.208
4.830
4.710
4.460

Table 1. Time-course induction of WLN6 protein showing steady increase in OD6oo with
time. The last column shows the amounts normalized by OD60o for loading on SDS
PAGE.
M O 30 60 90 120 180 210

WT.N6

Figure 6: 15% SOS-PAGE showing induction and expression of WLN6 protein in 1 mM
IPTG with increase in time. Time is shown in min.
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Production ofa 10 L batch ofWLN6 protein
· From the successful test induction and expression ofnative WLN6 protein, a 10 L
batch was produced in LB media containing similar concentration of kanamycin
following the protocol outlined earlier. The aim was to produce native WLN6 protein in
sufficient quantities for characterization. The cells were pelleted by centrifugation then
extracted for WLN6 protein by the freeze-thaw method. After harvesting and extraction,
the WLN6 crude extract was analyzed by SDS-PAGE. A strong band on SDS-PAGE gel
of about 7.5 kDa showed that WLN6 protein was expressed well in the 10 L
batch.WLN5-6 was successfully extracted using the freeze-thaw method and isolated by a
two step purification scheme involving anion exchange chromatography and gel filtration
chromatography.

Purification ofWLN6
Anion exchange chromatography
The freeze/thaw WLN6 extract was filtered then loaded onto a pre-equilibrated
DEAE Sepharose anion exchange column (Amersham Pharmacia Biotech) to isolate it
from other contaminating proteins. Proteins that bear negative charge at pH 6
preferentially bind to the positively charged DEAE resin while the neutral and positively
charged ones flow through without binding. The strength ofbinding of the proteins to the
column partially depends on the charge on the protein. Those that bind weakly are eluted
first at low ionic strength while those that bind strongly are eluted at higher salt
concentrations. WLN6 has a pl of 5.01 and therefore bears net negative charge at pH 6
(pH of the solvent buffer). This protein should ideally bind to the DEAE Sepharose anion
exchange column. Protein elution was monitored by the UV absorption profile at 254 nm.
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Polypeptides absorb UV light strongly around this wavelength. However, other
contaminant biomelecules like DNA and RNA also absorb UV light at the same
wavelength. The resulting fractions were also analyzed by the BioRad protein assay to
identify protein containing fractions and also to estimate protein concentration (Table 5).
SDS-PAGE was done to identify WLN6-containing fractions (Figure 7). SDS-PAGE
separates proteins based on size; the smaller proteins experience less resistance while
moving through the gel pores compared to the larger ones and therefore move faster
through the gel. To estimate the protein sizes more accurately, a set of protein standards
of known molecular weights were also ran alongside the protein samples.

Sample

Total protein concentration(µg/mL)

Pre-filtration supernatant

2744

Post filtration supernatant

2464

Flow-Through fraction 1

29.92

Flow-Through fraction 2

238.4

Flow-Through fraction 3

238.4

Table 2: Protein concentration at vanous steps of anion exchange chromatography
(DEAE) purification.
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M

F

22 24 26 28

30 32 34 36

45K
30K
20.1K
14.3
6.5K
3.5K

WLN6
Figure 7. SOS-PAGE of Anion exchange (DEAE) fractions.M is the Rainbow low
molecular weight marker, 22-36 are OEAE fractions, F is pre-filtered freeze-thaw extract.
WLN6 band of~7 kOa is present in fractions 22-36.
The BioRad protein assay showed that all the peak fractions contained protein but
at varied concentrations. Fractions 22-36 had the highest concentration. SOS-PAGE
analysis was used to identify WLN6-containing fractions. 10 µL were withdrawn from
each of the peak fractions, mixed with loading dye and water and run on a 15% Tricine
SOS-PAGE gel (Figure 7). The gel revealed that WLN6 eluted in fractions 22-36 which
corresponded to about 20% salt concentration (0.2 M NaCl). The ion exchange
chromatography concentrated WLN6 in fractions 22-36 but the SOS-PAGE revealed the
presence of other proteins of different molecular weights. To further isolate WLN6, size
exclusion chromatography (gel filtration) technique was used.

Gel filtration
This purification step was used to fractionate the proteins based on their sizes.
The WLN6 containing fractions from AEC were concentrated down to 2 mL using an
Amicon device fitted with a YM3 membrane. The concentrated protein solution was
loaded onto a Superdex G75 10/30 gel filtration column (Amersham Pharmacia) pre
equilibrated with MES buffer (20 mM MES/Na, pH 6.0, 150 mM NaCl, 10 mM OTT).
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SEC separates molecules based on size. Superdex G75 separates molecules in the range
of 3 to 75 kOa. In SEC, the larger molecules elute first while the smallest in column
range elute last. UV absorption at 254 nm was used to monitor elution of proteins. The
BioRad protein assay was used to identify protein containing fractions. The WLN6containing fractions were specifically identified by SOS-PAGE. Pure bands of~ 7.5 kDa
appeared on SDS-PAGE column between fractions 39-45 (Figure 8).
M

39 41 43 45

20.1K
14.3K
6.5K
3.5K

Pure WLN6

Figure 8: 15% Tricine SOS-PAGE of pure gel filtration fractions containing WLN6. M
indicates the low molecular wt. rainbow protein marker.
M D F G O F G
45K

30K
20.1K
14.3K

6.5K
3.5K

WLN6

Figure 9: 15% SDS-PAGE showing various stages of WLN6 purification. M denotes
protein marker. 0, F and G are samples withdrawn after anion exchange purification,
freeze-thaw extraction and gel filtration respectively.
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Expression of mutant WLN6(059 l D)
Strategene site-directed mutagenesis was successfully introduced on the native
pPOWD6 template to replace glycine to aspartic acid at the amino acid residue 591 in the
N-terminal domain of Wilson Protein (05910). Correctly designed primers were used to
introduce the mutation (05910) and this was confirmed by DNA sequencing.
Recombinant mutant WLN6 Plasmid was transformed in DH5a cells (E. coli)
cells and the plasmid isolated and purified (Figure 10 a). This plasmid was then
transformed in Rosetta (DE3) cells, inoculated in LB and induced with IPTO for protein
expression. Expression was analyzed by SOS-PAGE. (FigurelO). WLN6(0591D) protein
expression was successful. However; the protein could not be extracted from the bacterial
cells after several trials with different buffers including solubilization with 8M
guanidinium chloride. The point mutation probably interfered with the folding and thus
stability of the protein.

M 0.5

2

45K
30K
20.1K
14.3K
6.5K

3 4

WLN6(0591D)

3.5K

Figure 10: 15% SDS-PAOE showing a time-course induction of WLN6(0591D) protein
in 1 mM IPTO (shown with arrow); induction time is shown in hr.
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P N
45K
30K
20.1K
14.3K
6.5K
3.5K

M

N M

-

WLN6

Figure 11: Comparison between solubility of WLN6 and WLN6(G591D) in extraction
buffer (20 mM MES/Na, 10 mM DTT, pH 6). P is protein marker; N and M are native
and mutant WLN6 respectively.
Another strategy was developed after observing the good stability of native
WLNS-6 construct with varied concentrations of guanidinium chloride (GnHCl). Despite
being a strong denaturant, WLNS-6 titrated with GnHCl was still stable in up to 3M
GnHCl (H, 15 N-HSQC experiments in Florence, Italy) (Most proteins are completely
denatured in 2M GnHCI). Consequently, G591D mutation was successfully introduced in
the double construct WLNS-6 gene. The G591D mutation was confirmed by DNA
sequencing. The recombinant plasmid was transformed in Rosetta E. coli cells, inoculated
in LB and the protein expressed in lmM IPTG. The protein extraction levels were
insignificant to obtain a desirable protein concentration for NMR studies.
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M 30 60 120 180 240
45K
30K
20.1 K
14.3K
6.5K
3.5K

WLN5-6(G591D)

Figure 12: 15% Tricine SDS-PAGE showing a time-course induction of WLN56(G59 l D) mutant protein.
The third strategy was to improve the expression level of the mutant protein,
WLN5-6(G59 l D). Proteins are known to express better when they are cloned in a fusion
vectors. This strategy therefore employed the protocol of Ligation Independent Cloning
(UC) with vectors coding for glutathione transferase (GST) tag and thioredoxin tag. LIC
vectors were created by treating a linearized backbone with T4 DNA polymerase in the
presence of only one dNTP (dATP). The 3' to 5' exonuclease activity of T4 DNA
polymerase removes nucleotides until it encounters a residue corresponding to the single
dATP present in the reaction mix. At this point, the 5' to 3' polymerase activity of the
enzyme counteracts the exonuclease activity to effectively prevent further excision.
Plasmid sequences adjacent to the site of linearization are designed to produce specific
noncomplementary 13- and 14-base single stranded overhangs in the LIC vector. PCR
products with complementary overhangs were created by building appropriate 5'
extensions into the primers. The PCR product was purified to remove dNTPs (and
template plasmid) and then treated with T4 DNA polymerase in the presence of the
appropriate dNTP to generate the specific vector-compatible overhangs. The annealed
LIC vector and insert were transformed into competent E. coli cells. The positive clones
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were transformed in Nova blue giga E. coli strains. Protein expression was induced with
IPTG (Figure 13 A). The protein was expressed in fusion with GST and thioredoxin
respectively. The fusion protein (GST-WLN5-6(G591D) was purified by affinity column
(GST column) and eluted fractions collected for analysis (Figure 13 B).

A

B
45K
30K
20.1K
14.3K
6.5K
3.5K

Figure 13. A: Time course protein induction of GST fusion protein, GST-WLN56(G591D). Protein induction is observed at ~ 45 kDa. B: GST purified fusion mutant
protein.

Cleavage of the GST fusion tag
The GST and thioredoxin tags were cleaved using porcine enterokinase and
Factor Xa respectively. Gel analysis showed a positive GST cleavage of mutant WLN56(G591D) and GST fusion tag both running at the correct masses in the SDS-PAGE. The
cleavage for Factor Xa was not successful.

Figure 14: Porcine enterokinase cleavage of mutant GST- fusion protein (GST-WLN56(G591D). Lane 1 molecular marker, lane 2 and 3 represent enterokinase cleavage using
0.5 and 1 enzyme units respectively.
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Wilson Protein Domain 4 (mWD4) - Avitag
The cloned mWD4-Avitag plasmid was obtained from the laboratory of Professor
Peng Chen at Cornell University. This plasmid was transformed in Rosetta (DE3) cells
and inoculated in LB for protein induction and expression. The overexpressed protein
was extracted and purified using anion exchange chromatography and gel filtration. Pure
proteins were submitted for mass spectrometry before shipment to Cornell University.
mass spectrometry results indicated the correct mass.

WD4 avitag
Figure 15: Tricine SDS-PAGE (15%) showing pure fractions of mWD4-Avitag protein.
Lane 1; rainbow marker, lanes 2-4 denote different gel filtration fractions. Samples in
lanes 3 and 4 were treated with iodoacetamide.
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ID ( 1 H) NMR ofWLN6
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Figure 16. 1D proton NMR of native WLN6: Inset: Expanded spectrum of amide region.
The above NMR data was done at Centre for Magnetic Resonance, University of
Florence, Italy using a Bruker 700 MHz NMR machine. The amide region (chemical
shifts 5-10) show a good peak distribution and this is an indication of good protein
folding (Figure 16). To understand other parameters in terms of protein structures, it was
necessary to label the protein with both 1 sN and 13C.

1

H, isN Hetero Spin Quantum Correlation (HSQC)
The sN labeled native WLN6 was analyzed for HSQC using Bruker 700 high
1

frequency NMR in CERM, University of Florence. 8 scans were made during the data
acquisition. The H, 1 sN WLN6 protein displays broad distribution of NMR frequency also
observed in spread-out cross peak signals in the 1 H- 1 sN HSQC (Figure 17). Unfolded
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proteins normally show heavy overlap of signals on the 1 H- 15N HSQC spectrum. WLN6
is well folded according to the 2D 1 H- 15N HSQC spectrum (Figure 17). Assignment of
the 1 H- 15N HSQC spectrum is also consistent with the WLN6 protein sequence and the
number of amino acid residues. The distribution of signals is crucial for further structural
determination.
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Figure 17. 1 H, 15N HSQC signals for native WLN6. The cross-distribution of the signals
indicates a well-folded protein.

Nuclear Overhauser (NOESY) and TOCSY Experiments
The NOESY signals of a double-labeled WLN6 ( 15N and 13C-labeled) were
acquired alongside HSQC data. The signals were acquired with a Bruker-700 NMR
machine at 25°C in 150 ms. The signals obtained are well-distributed and correlates the
dipolar interaction of spins and orientation of protons in space (Figure 18). NOESY also
correlates protons which are distant in the amino acid sequence but close in space due to
tertiary structure. The scalar J coupling constants were calculated and used for structure
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calculation. The NOESY signals of the amide region were also acquired (Figure 19) for
complete assignment of the backbone signals.
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Figure 18: The NOESY signals of WLN6 at 298K.

A TOCSY experiment was also performed for WLN6 using Bruker-700 NMR
machine. The data was also acquired at 25°C in 50 ms scans (Figure 20). The signals
were also well-dispersed and an indication of well-folded protein. In the TOCSY
experiment, magnetization is dispersed over a complete spin system of an amino acid by
successive scalar coupling. The TOCSY experiment correlates all protons of a spin
system. Thus a characteristic pattern of signals results for each amino acid from which
the amino acid can be identified and subsequently assign the peaks. The peak
assignments were done manually using signal charts and the CARA computer program.
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Figure 21: Chemical shift difference (Oavg(HN)) due to superposition of HSQC data for
WLN6 and WLN5-6 on amino acid residues 79-146 (with respect to WLN5-6)

Solution NMR structure ofWLN6
The secondary structure of WLN6 was determined. The NMR structures of
WLN6 and WLN5-6 were compared by mapping the average chemical shifts (o
avg(HN)) of the HSQC data for both proteins. The data indicated that the superimposed
signal shifts (o avg(HN)) were less than 0.05 for majority peaks and therefore
insignificant (Figure 21). The structure WLN6 was calculated to be just the same as the
domain 6 region of WLN5-6 structure. The solution NMR structure shows that this
domain bears a ferrodoxin-like structure, pappap (Figure 22)). An analysis of WLN6
NMR data revealed the following secondary structural elements; P1(81-86), a1(94-103),
P2(109-114), P3(119-125), a2(132-140), P4(144-147) (Figure 22)(The residue numbers
correspond to domains 5 and 6 together) The Cys 91 and 94 which coordinate copper in
this metal binding domain are located in the first loop and first a-helix respectively.
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Cys 91

Cys 94

Figure 22: Ribbon-like MR structure of Wilson protein domain 6. Cys 91 and 94
indicate the cysteine residues involved in binding copper in the CXXC motif. The residue
numbers correspond to domains 5 and 6 together.
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CHAPTER IV
DISCUSSION
To better understand the disease-causing mutation of Wilson protein
domain 6, both native and mutant WLN6 constructs were expressed in vitro. The
first step was to obtain the wildtype (native) form of this protein. The sequence of
the sixth domain of wildtype ATPB7 gene was amplified by PCR, sub-cloned in
pET24d vector, and overexpressed in E. coli cells. The expressed protein was
extracted from bacterial cells using freeze-thaw extraction method, and then
subjected to two purification steps: anion exchange chromatography and size
exclusion chromatography (gel filtration). The column used in the anion exchange
chromatography was diethylaminoethyl (DEAE). Table 5 shows that majority of
soluble cellular proteins bound to the DEAE column after loading and washing
steps. WLN6 was expected to bind to the column because the pH of the solvent
buffer (20 mM MES/Na, pH 6) was slightly higher than its pl (5.2). Since the
column was also run at pH 6, WLN6 would posses an overall negative charge.
This would facilitate electrostatic interaction between the protein (negatively
charged) and the positively charged diethylaminoethyl therefore WLN6 was
retained on the resin. Elution of WLN6 was realized in low salt concentration
relative to other proteins which also bound to the column. This suggests the
contaminant proteins are more acidic, relative to WLN6 and confirms that the pl
of WLN6 is indeed slightly lower than pH 6 (our measured pl of WLN6 is 5.2).
While DEAE step initiated the protein purification process, the analytical gel from
this purification still confirmed the presence of other contaminant proteins of
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higher molecular weight (Figure. 7). These contaminant proteins necessitated the
next purification step; gel filtration. In the gel filtration column, WLN6 eluted
among the last protein-containing fractions. This shows that the size of this
protein is smaller (~7 kD) compared to other proteins as observed in the SDS
pAGE (Figures 7, 9). The results from gel filtration indicate complete purification
of WLN6 (Fig. 8). To study the disease-causing mutation, point mutagenesis of
the WLN6 native plasmid DNA was carried out.
The mutation, G591D, was successfully introduced and confirmed by
DNA sequencing. A time-course induction study of WLN6(G591D) expressed in
Rosetta (DE3) cells showed that expression of this protein was positive in
millimolar concentrations of IPTG. T7 polymerase then transcribes the mutated
gene for domain 6 located on the pET24d vector. Rosetta (DE3) strains of E. coli
were utilized for protein expression because they contain a chromosomal copy of
T7 RNA polymerase, which is inducible by lac UV5 promoter. In addition, these
strains of cells lack membrane proteases that could potentially degrade proteins
(including WLN6) during purification. Figure 10 shows that WLN6(G591D) is
inducible by IPTG. However, the mutant WLN6(G591D) was not easily extracted
in freeze-thaw extraction buffer (the buffer that easily extracts native WLN6
protein). Several extraction attempts were made by changing the buffer conditions
and composition. The protein extraction was still unsuccessful. The bacterial
pellets containing the mutant protein were further subjected to sonication but still
the extraction was not successful. We finally sought the use of a commercial
extraction reagent from Novagen. BugBuster® Protein Extraction Reagent is
formulated to gently disrupt the cell wall of E. coli and liberate soluble proteins. It
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provides a simple, rapid, low-cost alternative to mechanical methods such as
French press or sonication for releasing expressed target protein in preparation for
purification or other applications. The protein was still not extracted from the
pellets even after using this reagent. It was concluded that the mutant protein was
an inclusion body and therefore solubilization techniques would be the last
preferred method for its extraction. Solubilization of bacterial pellets involves the
use of chaotropic agents (urea and guanidine hydrogen chloride) at higher
concentration (Arakawa & Timasheff, 1984). A higher concentration of
Guanidinium Chloride was used to solubilize bacterial pellets and denature the
mutant protein, but when the protein was exchanged in a refolding buffer, it
precipitated out in both low and high salt buffers. Another strategy was developed
after observing the stability of native WLN5-6 protein with varied concentrations
of Guanidinium chloride (GnHCl). Despite being a strong denaturant, WLN5-6
titrated with GnHCl was still stable in up to 3M GnHCl (H, 15N-HSQC
experiments in Florence, Italy, data unpublished) (Note: Most proteins are
completely denatured in 3M GnHCl). With the hypothesis that the native stable
WLN5-6 is more stable due to the additional domain 5, a mutant protein also
containing domain 5 may also impart stability to the mutant protein, WLN56(G591D). Therefore G591D mutation was successfully introduced in the double
construct template and the mutagenic plasmid was tested for protein expression.
However, the WLN5-6(G591D) protein extraction levels were also insignificant
to obtain a desirable amount of protein for NMR studies although little amounts
were realized for CD studies.
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In another attempt to increase the solubility and expression levels of the mutant
WLN5-6(G591), the plasmid was re-cloned in both GST and thioredoxin fusion since the
expression levels for fusion proteins are known to be significant. The LIC clones were
expressed for the mutant fusion proteins and extracted from the cells successfully. After
purification with HisTag and GST columns, both enterokinase and Factor Xa fusion
cleavage was performed to isolate the pure mutant proteins. The cleavage was not
successful and this led us to question the sequence. The LIC recombinant plasmids were
re-submitted for protein sequencing and there was an indication of an insertion of 5 base
pairs just after the point of mutation.
1

H NMR data of the native WLN6 protein indicates a good protein folding as

observed by well-dispersed peaks in both amide ( 1 H chemical shifts 6-10 ppm, Fig 16)
and side chain regions ( 1 H chemical shifts 0-3 ppm, Fig 16). The numerous chemical shift
peaks seen for amide protons between 6.5-9.5 ppm, for the alpha protons 3-5 ppm and for
aliphatic protons 0.5 ppm to 3 ppm is a clear indication that the sample was in a stable
condition, optimal for NMR experiments.
To obtain the structure of the native form of WLNP, the protein was expressed in
complete minimal media enriched with

15

N and

13C

to ensure incorporation of these

NMR-active elements in the structure of the protein. The use of heteronuclei,
1

3 C,

15

N and

allows some new features in NMR which facilitate the structure determination.

However, their natural abundance and gyromagnetic ratio are markedly lower than that of
the proton. Two strategies used to increase the low sensitivity of these nuclei are isotopic
enrichment of these nuclei in proteins and enhancement of the signal to noise ratio by the
use of inverse NMR experiment in which the magnetization is transferred from protons to
the heteronucleus (HSQC). Other reasons for using
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15

N and

1

3C

to label WLN6 are

because they are not radioactive and therefore harmless and they have a spin of ½ and
therefore can only have two quantum energy levels.
The 2D HSQC spectrum of WLN6 (Figure 17) was consistent with the WLN6
amino acid sequence and this was a key step it solving the structure of native WLN6
protein. The 2D HSQC data shows well-dispersed signals and resonance. This shows that
WLN6 is well-folded and in stable condition. The sharp dispersed signals on HSQC
spectrum is also a good indicator of optimal NMR experiment conditions and the
monomeric nature of WLN6. Monomeric proteins show sharp signals on HSQC
spectrum. An amino acid residue assignment of all the HSQC signals was done to
determine the backbone structure of the protein.
3D NOESY (Figures 18, 19) and TOCSY (Figure 20) experiments were also done
to establish the orientation of the side chains and bond angles respectively. The distances
derived from nuclear Overhauser effect (NOE) spectra were converted into three
dimensional structures by computer algorithms (CARA program). The native structure of
WLN5-6 was also calculated using its HSQC data, NOESY and TOCSY data. Besides
these data, the J coupling constraints and the relaxation measurements were also available
for native WLN5-6. By mapping the HSQC data of WLN6 to the WLN5-6, we were able
to calculate the two-dimensional chemical shift difference these . two proteins. The
chemical shift difference (8avg(HN)) of the HSQC signals in WLN6 with respect to
WLN5-6 (except amino acid residue 124) was below 0.05. (Figure 20) The chemical shift
difference is considered insignificant if below 0.05. However, the first 5 residues (79-83)
show a> 0.05 average chemical shift difference and but these values show a decrease
towards the 83rd residue. We believe that this is the effect of domain 5 on domain 6
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which affects the chemical environment of the first few residues in domain 6 and thus the
significant chemical shift difference.
Based on the HSQC assignment, NOESY, TOCSY data and the HSQC mapping,
the structure of WLN6 was calculated. WLN6 was resolved to have a ferroxidin-like

pappap (Figure 22) which is in agreement with the predicted model (Figure 2). WLN6
structure is monomeric and assumes a similar structure even its multi-construct form. The
recently published structure of WLN5-6 (Achila et al, 2006) also sheds more light on
Wilson protein.
The CD data obtained for mutant protein WLN5-6(G591D) indicates that the
number of a- helices constitute a one-third fraction of the entire motif. This may indicate
that the overall

pappap is still maintained in the mutant protein, WLN6(G591D).

The

NMR structure of native WLN6 indicates that Glycine 591(mutated to D in mutant
protein) is situated at the protein loop at the beginning in the beginning of the second

P

sheet. This mutation could possibly hinder the flexibility of the protein loop rendering the
mutant protein unstable with subsequent low solubility which might hinder the normal
function of the protein. In a similar study of A629P mutant of Menkes protein, a WLNP
homologue, (Banci et al, 2005), the authors suggest that the mutation makes the protein
beta sheet more solvent accessible, possibly resulting in an enhanced susceptibility of
+

ATP7 A to proteolytic cleavage and/or in reduced capability of Cu translocation. This
similar mechanism may be in play in this mutation since the mutation is situated at the
beginning of the beta sheet. To validate this fact, an NMR solution structure of this
mutant protein should be resolved. To understand why this apparently minor amino acid
replacement is pathogenic, the solution structures and dynamics on various time-scales of
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+

wild-type and WLN6(G591D) should be determined both in the apo- and Cu -loaded
forms. The interaction in vitro with the physiological ATP7B copper (!)-donor (HAHl)
should be additionally studied.

Conclusion
We have cloned, expressed and purified the native form of WLN6. We have expressed
the disease-causing mutant protein as a 2-domain construct WLN5-6(G591D). The CD
data of these two proteins predict an a.-helicity of 23%. The solution NMR structure of
the native WLN6 reveals a monomer with a

pappap ferroxidin-like fold.

We propose

that the mutant form of this protein, WLN6(G591D), may have a similar overall fold to
the native protein based on the CD data. This is also consistent with the recently
published mutant domain 6 (MKL6(A629B) structure of an analogous protein, MNKP
(Banci & Bertini & Cantini & Migliardi et al., 2005). In addition we propose a similar
mechanism in copper-uptake impairment between these two mutant proteins based on the
position of both mutations.
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